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Abstract
Proper growth of blood vessels is critical for development, wound healing and homeostasis. This process is
regulated by a variety of microenvironmental cues including growth factor signaling, cell-cell contacts and
mechanical and biochemical signals from the extracellular matrix. The work presented in this dissertation
encompasses the application of engineering principles to the study of angiogenesis and vascular biology
within the contexts of tissue engineering and vascular disease.
In Chapter 2, we present a novel strategy for generating a spatially patterned vascular network in vivo. Future
development of clinically viable engineered tissues hinges on the ability to generate functional vasculature
capable of delivering blood to parenchymal cells deep within the tissue. The vascularization strategy described
here utilizes tissue constructs that contain patterned ‘cords’ of endothelial cells. Implantation of these
constructs into mice leads to the formation of stable capillaries in a spatially controlled geometry. The
capillaries become perfused with host blood as early as 3 days post implantation, remain stable for at least 28
days in vivo, are largely comprised of implanted endothelial cells, and are invested by α-SMA positive
pericytes. We further demonstrate that spatial patterning of vascular architecture improves the function of
engineered hepatic tissues. Specifically, co-implantation of patterned endothelial cell cords with primary
hepatocyte aggregates suggested that organized vascular architecture significantly improved albumin
promoter activity within the tissues.
In Chapter 3, we describe the development of an organotypic vascular wall model and show that pulmonary
arterial smooth muscle cells (PASMCs) isolated from patients with idiopathic pulmonary arterial
hypertension (IPAH) exhibit a hyperproliferative phenotype in culture. While normal control PASMCs
display Rac1-mediated growth control, the higher proliferation in IPAH PASMCs is dependent on increased
RhoA activity. We observed that focal adhesion assembly and focal adhesion kinase signaling are abnormally
increased in IPAH PASMCs and show that antagonizing adhesion signaling by direct inhibition of FAK
abrogates IPAH PASMC hyperproliferation in vitro.
In summary, our strategy for rapidly inducing the formation of spatially controlled capillaries comprises a
novel technique for spatial control of vessel growth in vivo. Functional studies with engineered hepatic tissues
also demonstrate the potential of this technique to be used in vascularizing engineered solid organs. Findings
from our investigation into aberrant IPAH SMC proliferation suggest that a mechanosensitive proliferative
control mechanism underlies IPAH etiology.
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ABSTRACT 
ENGINEERING PATTERNS TO STUDY VASCULAR BIOLOGY 
Jan D. Baranski 
Christopher S. Chen 
 
Proper growth of blood vessels is critical for development, wound healing and 
homeostasis. This process is regulated by a variety of microenvironmental cues including 
growth factor signaling, cell-cell contacts and mechanical and biochemical signals from 
the extracellular matrix. The work presented in this dissertation encompasses the 
application of engineering principles to the study of angiogenesis and vascular biology 
within the contexts of tissue engineering and vascular disease. 
In Chapter 2, we present a novel strategy for generating a spatially patterned 
vascular network in vivo. Future development of clinically viable engineered tissues 
hinges on the ability to generate functional vasculature capable of delivering blood to 
parenchymal cells deep within the tissue. The vascularization strategy described here 
utilizes tissue constructs that contain patterned ‘cords’ of endothelial cells. Implantation 
of these constructs into mice leads to the formation of stable capillaries in a spatially 
controlled geometry. The capillaries become perfused with host blood as early as 3 days 
post implantation, remain stable for at least 28 days in vivo, are largely comprised of 
implanted endothelial cells, and are invested by α-SMA positive pericytes. We further 
demonstrate that spatial patterning of vascular architecture improves the function of 
engineered hepatic tissues. Specifically, co-implantation of patterned endothelial cell 
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cords with primary hepatocyte aggregates suggested that organized vascular architecture 
significantly improved albumin promoter activity within the tissues. 
 In Chapter 3, we describe the development of an organotypic vascular wall model 
and show that pulmonary arterial smooth muscle cells (PASMCs) isolated from patients 
with idiopathic pulmonary arterial hypertension (IPAH) exhibit a hyperproliferative 
phenotype in culture. While normal control PASMCs display Rac1-mediated growth 
control, the higher proliferation in IPAH PASMCs is dependent on increased RhoA 
activity. We observed that focal adhesion assembly and focal adhesion kinase signaling 
are abnormally increased in IPAH PASMCs and show that antagonizing adhesion 
signaling by direct inhibition of FAK abrogates IPAH PASMC hyperproliferation in 
vitro. 
 In summary, our strategy for rapidly inducing the formation of spatially controlled 
capillaries comprises a novel technique for spatial control of vessel growth in vivo. 
Functional studies with engineered hepatic tissues also demonstrate the potential of this 
technique to be used in vascularizing engineered solid organs. Findings from our 
investigation into aberrant IPAH SMC proliferation suggest that a mechanosensitive 
proliferative control mechanism underlies IPAH etiology. 
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
 
1.1 Scope of dissertation 
Two studies are presented in this dissertation. In Chapter 2, we describe the development 
and application of a novel strategy for vascularizing engineered tissues in vivo. In 
Chapter 3, while we begin with a description of work aimed at developing an organotypic 
arterial wall model, our main focus shifts to a study into proliferative control mechanisms 
that might underlie smooth muscle cells in pulmonary arterial hypertension. A common 
introduction to these two studies is presented here in Chapter 1 and is organized as 
follows: 1) brief definition and overview of tissue engineering, 2) introduction to 
angiogenesis and vascular biology, 3) overview of strategies for promoting angiogenesis 
via tissue engineering approaches, and 4) introduction to the pathology of vascular 
disease and pulmonary arterial hypertension. Topics including remaining challenges and 
future directions are discussed in Chapter 4. 
 
1.2 Introduction to tissue engineering 
As medical technology improves and life expectancy throughout the world increases, the 
demand for organs grows.  Currently, approximately 500,000 patients benefit from organ 
transplants in the US each year, and millions of additional surgical procedures are 
performed to help replace or reconstruct damaged tissue (Langer & Vacanti, 1993; 
Network & Recipients, 2011).  The number of organs available for transplant, however, 
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continues to severely outpace demand by an ever-greater margin. Indeed, the median 
waiting period for a kidney in the US in 2005 was 1,269 days (Network & Recipients, 
2011). Apart from whole organ transplants, therapies utilizing tissue regeneration or 
replacement hold much promise for treating a variety of conditions. Considering diabetes 
alone, the potential is enormous – 17.5 million patients were affected in the US in 2007, 
and the disease represents a $116 billion annual burden in excess medical expenditures 
(American Diabetes Association, 2007). 
Since first being described in the late 1980s, the field of tissue engineering is 
slowly beginning to meet some of the demands for organs and organ replacement 
therapies. Its goal is to develop biological substitutes that maintain, improve or restore 
normal tissue function (Heineken & Skalak, 1991; Langer & Vacanti, 1993; Vacanti, 
2012). Tissue engineering embodies efforts to create new therapies that rely on a 
fundamental understanding and control of the structure-function relationship in native 
tissues. It is an inherently multidisciplinary field that marries the application of 
engineering principles with a fundamental understanding of the underlying biological 
processes (Orlando, Wood, et al., 2011b). Though clinical trials with tissue-engineered 
therapies have only recently begun, preliminary results from these and other in vitro and 
preclinical animal studies strongly suggest that many novel therapies will emerge over 
the next several decades. 
1.2.1 General strategies in tissue engineering 
Tissue engineering originally emerged from the biomaterials field in the 1980s – as the 
biophysical properties of natural and synthetic materials were becoming better 
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understood, a growing number of studies utilizing these materials and their interactions 
with cells as a means of repairing or replacing injured tissues quickly coalesced into its 
own field (Vacanti, 2012). Today, tissue engineering strategies can be divided into two 
general categories: 1) ones that rely solely on growth-inducing substances and scaffolds 
and 2) ones that rely on cells placed on or within synthetic scaffolds or natural matrices 
(Langer & Vacanti, 1993). Accordingly with the field’s origins, a substantial amount of 
research has focused on efforts to generate materials with bioactive properties (R. R. 
Chen & Mooney, 2003; Lutolf & Hubbell, 2005). Indeed, within the context of vascular 
tissue engineering, much work has focused on using biomaterials to help drive the body’s 
natural angiogenic processes (Cleary et al., 2012; Lovett, Lee, Edwards, & Kaplan, 2009; 
Phelps & García, 2010). Significant contributions in this area include the controlled 
release of growth factors for inducing vessel growth (Peters, Polverini, & Mooney, 2002), 
insights into of the role of matrix mechanics on capillary morphogenesis (Ghajar, Chen, 
Harris, Suresh, et al., 2008a), and the development of a variety of synthetic materials with 
broad applications in tissue engineering (Lin & Anseth, 2008; X. Liu, Holzwarth, & Ma, 
2012). 
To date, tissues with cells of virtually every type have been created in the 
laboratory (Orlando, Baptista, et al., 2011a; Orlando, Wood, et al., 2011b). A critical 
issue, however, has been a limitation in the number of autologous cells that are available 
for use in patients (C. J. Koh & Atala, 2004; Rustad, Sorkin, Levi, Longaker, & Gurtner, 
2010). The discovery of inducible pluripotent stem cells in 2006 has provided a potential 
solution to the problem of cell source and cell-based therapies are seeing much renewed 
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interest (Rustad et al., 2010). While significant challenges remain, advances in the study 
of materials and cell biology are continuing to drive the development of novel and 
increasingly effective tissue-engineered therapies. 
 
1.2.2 Current challenges in engineering solid tissues 
Therapies for replacing organs such as engineered skin, bladder, airways, urethra and 
large blood vessels have recently showed promise in early stage clinical trials and have 
already become available to small numbers of patients (Hibino et al., 2011; Macchiarini 
et al., 2008; Orlando, Wood, et al., 2011b; H. Yanaga, Imai, Fujimoto, & Yanaga, 2009). 
The ability to engineer large solid organs with high metabolic demands such as kidney, 
liver and pancreas, however, remains elusive.  These cell dense and highly vascularized 
tissues are complex and remain difficult to construct in the laboratory (Vacanti, 2012).  A 
key obstacle to their design is the limitation of diffusion of nutrients and waste products 
to and from cells within the tissue. Since cells must be located within 100 - 200 µm of 
blood vessels to ensure survival, our ability to create a functional vasculature remains 
paramount to overcoming the challenge of creating large organs for use in humans 
(Rouwkema, Rivron, & van Blitterswijk, 2008). The development of a strategy to 
effectively vascularize engineered tissue is a major goal of the work described in Chapter 
2 of this dissertation. 
1.2.3 Organotypic models of vascular smooth muscle 
An ancillary goal within the field of tissue engineering is to generate physiologically 
relevant models of normal and diseased tissues (Garlick, 2007; Inamdar & Borenstein, 
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2011; Paquet et al., 2010). Such models allow a much wider variety of manipulations and 
are used for the in vitro study of phenomena that might otherwise be prohibitively 
expensive, time consuming, or invasive for in vivo experimentation. In the context of 
vascular biology, current organotypic models include microfluidic devices and similar 
systems that mimic one or more physiological processes within angiogenesis, vascular 
injury, inflammation, and tumor extravasation (Chrobak, Potter, & Tien, 2006; Kamat et 
al., 2011; Zervantonakis et al., 2012; Zheng et al., 2012). While the adoption of 
endothelial-only angiogenic models has been growing significantly, the development of 
more complete arterial wall models has been largely unexplored. Indeed, the few reported 
uses of an in vitro EC-SMC bilayer focus on the direct interactions between ECs and 
SMCs, and we found no reports of its use to study disease (Fillinger, Sampson, 
Cronenwett, Powell, & Wagner, 1997; Niwa, Sakai, Watanabe, Ohyama, & Karino, 
2007; Ziegler, Alexander, & Nerem, 1995). In a study presented in Chapter 3 of this 
dissertation, we sought to create an organotypic model of vascular smooth muscle for use 
in the study of pulmonary arterial hypertension.  
Given that smooth muscle cells often differentiate into a synthetic phenotype when 
cultured in traditional tissue culture models (Thyberg, Hedin, Sjölund, Palmberg, & 
Bottger, 1990), we predicted that an organotypic model such as the one described here 
might allow for additional study of IPAH pathobiology in a more physiologically relevant 
context. 
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1.3 Angiogenesis in physiology and disease 
Angiogenesis, or the sprouting of capillaries from preexisting blood vessels, is a complex 
process that relies on a number of spatiotemporally regulated biochemical and 
mechanical cues . When tissues within multicellular organisms grow to sizes beyond the 
diffusion limit, they rely on angiogenesis to recruit new vessels and gain access to the 
blood supply (Carmeliet & Jain, 2000). Furthermore, formation of a functional 
vasculature is critical for tissues’ ability to receive nutrients and remove metabolic waste, 
and angiogenesis plays a central role in development, wound healing and a number of 
disease states with each step regulated by a balance between pro- and anti-angiogenic 
cues . 
1.3.1 Steps of angiogenesis 
Angiogenesis requires the cooperative signaling of a variety of growth factor-mediated 
biochemical and matrix-mediated adhesive and mechanical cues. The process begins with 
the stimulation of quiescent endothelial cells within existing vessels by proangiogenic 
cues (D'Amore & Thompson, 1987). Growth factors such as vascular endothelial growth 
factor (VEGF) first stimulate the normally quiescent endothelial cells to begin degrading 
the surrounding extracellular matrix (Ferrara, Gerber, & LeCouter, 2003). During these 
first steps of angiogenesis, the now active endothelial cells begin secreting matrix 
metalloproteinases (especially MMP1, MMP2 and MT1-MMP) to degrade the basal 
lamina and the surrounding adventitial matrix (Adams & Alitalo, 2007; Carmeliet, 2003). 
Concurrently, the cells begin proliferating and migrating away from the original vessel 
and towards the source of guidance cues such as gradients of VEGF or gradients of 
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neural guidance cues such as semaphorins and plexins (Torres-Vázquez et al., 2004). The 
intricate sprouting process is further regulated notch and delta-like-4 (Dll4) interactions 
in the emerging sprout (Phng & Gerhardt, 2009). While individual endothelial cells first 
initiate the sprouting process, the emerging sprout consists of numerous stalk cells 
following the guidance of a leader, or tip cell. The sprouting cells actively compete for 
the tip cell position in a process that involves the up- and down-regulation of VEGF 
receptors and is mediated by Notch and Dll4 signaling (Jakobsson et al., 2010). As 
sprouting continues, additional gradients of molecules including platelet-derived growth 
factor B (PDGFB) and angiopoietin help recruit supporting pericytes to the nascent 
endothelial sprouts (Hellberg, Ostman, & Heldin, 2010; Jain, 2003). At this stage of 
angiogenesis, the newly formed vessels begin to form lumens capable of carrying blood 
via a process of vacuole fusion (Kamei et al., 2006; Strilic et al., 2009). The maturing 
vessels are further stabilized by the presence of blood flow, establishment of tight 
junctions via cell-cell interactions between claudins and occludins, and adherens 
junctions via VE-cadherin interactions (Dejana & Giampietro, 2012; Dejana, Tournier-
Lasserve, & Weinstein, 2009; Jain, 2003). Ultimately, all of these tightly coordinated 
steps lead to the development of functional, blood-carrying vessels that may be further 
pruned in order to generate an optimal network of vessels capable of effectively 
delivering blood to growing or injured tissues (Hlushchuk et al., 2011). Lastly, the 
dysregulation of vessel growth contributes to the pathogenesis of many disorders 
including pulmonary hypertension (Adams & Alitalo, 2007; Carmeliet, 2003; Carmeliet 
& Jain, 2011). 
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1.3.2 Regulation of angiogenesis by growth factors 
The process of angiogenesis is regulated by a diversity of cues from growth factors, the 
ECM, and cell-cell interactions. Of the soluble factors that regulate angiogenesis, the 
VEGF signaling pathway has been the most widely studied. The VEGF gene family 
consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF) 
(Ferrara et al., 2003). By far, the most studied isoform is VEGF-A, which signals 
primarily through VEGFR2 (Adams & Alitalo, 2007). It is essential for embryonic 
angiogenesis and deletion of a single allele results in embryonic lethality (Carmeliet et 
al., 1996). In general, VEGF-A has been found to be critical for all tissues and 
developmental stages in which vessel growth is essential. The VEGF isoforms are 
capable of binding to a set of receptor tyrosine kinases, mainly VEGFR-1, VEGFR-2 and 
VEGFR-3 (Adams & Alitalo, 2007; Ferrara et al., 2003). VEGFR-2 seems to play a 
primary role in modulating the growth and permeability actions of VEGF, and studies 
have shown that its knockout in mice leads to a lethal defect in which the vasculature 
fails to properly form (Shalaby et al., 1995). In contrast, studies have suggested that 
VEGFR-1 may play an inhibitory role by suppressing signaling through VEGFR-2. In 
mice, knockout of VEGFR-1 leads to an excess of endothelial cells that assemble into 
non-functional disorganized tubules (Fong, Rossant, Gertsenstein, & Breitman, 1995). 
While the role of VEGFR-3 is still not entirely clear in angiogenesis, it has been shown to 
be important in sprouting and tip cell regulation, lymphatic vessel development, and most 
recently, in tumor progression (J.-L. Su et al., 2006; Taipale et al., 1999).  
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Platelet-derived growth factor (PDGF) is critical to the later stages of the 
angiogenic process (Jain, 2003). Once sprouting is underway, endothelial cells release 
PDGF-B to recruit pericytes, which express PDGF receptor-beta (Gaengel, Genové, 
Armulik, & Betsholtz, 2009; Hellberg et al., 2010). In vivo studies have shown that 
knockout of PDGF-B leads to pericyte deficiencies, which result in fragile and leaky 
vessels (Quaegebeur, Segura, & Carmeliet, 2010). PlGF, first thought to be a 
proangiogenic factor critical during development, is dispensable during development and 
is relevant only in disease(Carmeliet et al., 2001). Similar to VEGF, basic fibroblast 
growth factor was one of the first angiogenic factors to be discovered (Carmeliet & Jain, 
2011). bFGF and the related family of FGFs bind to FGF receptors (FGFRs) on 
endothelial cells or can stimulate angiogenesis indirectly by inducing the release of 
angiogenic factors from other cell types (Beenken & Mohammadi, 2009). Most notably, 
the inhibition of FGFR signaling in quiescent endothelial cells wash shown to cause 
vessel disintegration, suggesting that basal levels of FGF are required for the 
maintenance of vascular integrity (Murakami et al., 2008). 
Recently, a number of studies have focused on the role of the Ang/Tie signaling system 
in angiogenesis (Carmeliet & Jain, 2011). This signaling pathway consists of two 
receptors, Tie-1 and Tie-2, and three ligands, Ang-1, And-2 and Ang-4. Overall, the 
Ang/Tie receptor/ligand system provides a switch between maintaining vessel quiescence 
and allowing existing vessels to respond to angiogenic stimuli. Ang-1 functions as a Tie2 
agonist and is released by mural cells, while Ang-2 is a competitive Ang-1 antagonist and 
is released by endothelial tip cells (Augustin, Koh, Thurston, & Alitalo, 2009; Gaengel et 
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al., 2009). In quiescent endothelial cell layers such as those present in mature vessels, 
Ang-1 helps further stimulate quiescence by causing Tie2 clustering at cell-cell junctions, 
recruiting additional mural cells, and stimulating basement membrane deposition 
(Saharinen et al., 2008). In an angiogenic context, however, endothelial tip cells release 
Ang-2, which antagonizes Ang-1/Tie2 signaling and causes increased angiogenic activity 
through enhanced mural cell detachment, increased vascular permeability through 
loosening of cell-cell junctions, and eventually increased endothelial cell sprouting 
(Augustin et al., 2009). 
The most recently implicated signaling system in angiogenesis is the Notch 
signaling pathway. During sprouting, activation of VEGFR-2 in tip cells upregulates the 
expression of Dll4, a soluble ligand for the Notch receptor (Hellström et al., 2007; Phng 
& Gerhardt, 2009). In turn, the Notch activation in neighboring endothelial cells 
downregulates VEGFR-2 and upregulates VEGFR-1, making the stalk cells less 
responsive to the sprouting activity of VEGF. This interplay between VEGFR-1 and 
VEGFR-2 expression in neighboring cells coordinates the cells’ migration toward the tip 
cell position within growing sprouts (Gaengel et al., 2009; Jakobsson et al., 2010). 
The angiogenic process is tightly regulated by a complex milieu of growth 
factors, which are only briefly discussed here. Many additional intricacies in the 
regulation of angiogenesis by soluble factors such as Dll4/Notch-mediated competition 
between tip and stalk cells, crosstalk between different VEGF isoforms and its receptors, 
and the guidance of sprouts via hypoxic and neurovascular guidance cues are also recent 
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topics of investigation (Arima et al., 2011; Greenberg et al., 2008; Jakobsson et al., 
2010). 
1.3.3 Regulation of angiogenesis by the extracellular matrix 
The ECM provides cells with a physical anchorage to their surrounding environment and 
is often a dynamic component of the cellular microenvironment. Vascular cells adhere to 
the surrounding ECM through integrins and actively degrade and secrete new matrix 
during periods of angiogenic activity (Carmeliet, 2003; D'Amore & Thompson, 1987). 
Due to the heterodimeric nature of integrins and their ability to signal bidirectionally, 
integrin signaling during angiogenesis is both more complex and less well understood 
than growth factor signaling. While not all integrins are expressed in quiescent 
endothelium, integrins α1β1, α2β1, α4β1, α5β1, α6β1, α9β1, α6β4, αvβ3 and αvβ5 have 
all been implicated in angiogenesis (Avraamides, Garmy-Susini, & Varner, 2008; 
Desgrosellier & Cheresh, 2010; Hodivala-Dilke, 2008). Animal and in vitro studies and 
have shown that blocking integrin αvβ3, αvβ5, α5β1, α1β1, or α2β1 inhibits angiogenesis 
in vivo or in ex vivo angiogenic models (Brooks, Silletti, Schalscha, Friedlander, & 
Cheresh, 1998; Friedlander et al., 1995; Kim, Bell, Mousa, & Varner, 2000; Senger et al., 
1997). Integrins αvβ3 and αvβ5 are particularly well studied and appear to be upregulated 
in response to proangiogenic factors in both healthy tissues and in tumors (Avraamides et 
al., 2008; R. Silva, D'Amico, Hodivala-Dilke, & Reynolds, 2008). Further complexity, 
however, is suggested by integrin knockout studies, which suggest that integrins αv, β3, 
β5 and α2 are not always required for angiogenesis (Bader, Rayburn, Crowley, & Hynes, 
1998; X. Huang, Griffiths, Wu, Farese, & Sheppard, 2000; Zhang et al., 2008).  
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Given integrins’ ability to transmit signals bidirectionally across the cell 
membrane and to interact with a variety of extracellular molecules, they are said to 
function as hubs that coordinate endothelial cell behavior during angiogenesis (Contois, 
Akalu, & Brooks, 2009). Specifically, integrins possess the ability to bind to growth 
factors such as VEGF, bFGF, and Ang-1 as well as receptors including VEGFR-2 and 
FGFR (Avraamides et al., 2008). These interactions have been shown to stimulate vessel 
growth by upregulating and activating proteases secreted by invading tip cells and 
promoting vessel maturation by enhancing the adhesion of endothelial cells and pericytes 
to their shared basement membrane (Desgrosellier & Cheresh, 2010; Hodivala-Dilke, 
2008). 
 Finally, it is important to note the role of the ECM components in regulating 
angiogenesis. Endothelial cells and the surrounding pericytes share a basement 
membrane that is primarily composed of laminin and type IV collagen (Carmeliet, 2003; 
Simon-Assmann, Orend, Mammadova-Bach, Spenlé, & Lefebvre, 2011). During 
sprouting, the basement membrane and surrounding ECM components must be degraded 
in order to allow for the migration of emerging sprouts. Upon induction of angiogenic 
sprouting, proteases such as MT1-MMP proteolytically degrade the basement membrane 
and expose cryptic chemotactic motifs in the ECM (Carmeliet, 2003; Chun et al., 2004). 
The degradation of the surrounding matrix allows for the deposition of provisional matrix 
proteins such as fibronectin and denatured collagen, which again signal through integrins 
(Arroyo & Iruela-Arispe, 2010). In addition, the newly exposed cryptic binding sites 
provide additional proangiogenic signaling cues that were not present in the quiescent 
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state (Ghajar, George, & Putnam, 2008b). A specific example includes the cleavage of 
type IV collagen, which exposes cryptic binding sites that bind upregulated αvβ3 
integrins during angiogenesis (J. Xu et al., 2001). During quiescence, the presence of the 
surrounding ECM components helps maintain endothelial cells in an antiproliferative 
state (Carmeliet & Jain, 2011). Lastly, MMPs help regulate the angiogenic process by 
liberating matrix-bound growth factors such as VEGF and FGF (Bergers et al., 2000). 
While matrix bound isoforms of VEGF have been shown so support vessel branching, 
soluble VEGF that has been cleaved by MMPs has been shown to enlarge vessels (Iruela-
Arispe & Davis, 2009). An additional layer of complexity is introduced into the 
regulation of angiogenesis by proteases due to their ability to release anti-angiogenic 
signals such as angiostatin (Folkman, 2007). 
1.3.4 Regulation of angiogenesis by cell-cell contacts 
Due to the multicellular nature of blood vessels, cell-cell junctions play a fundamental 
role in all steps of angiogenesis (Nguyen & D'Amore, 2001). Notably, a major form of 
endothelial cell-cell signaling occurs through gap junctions via the connexin family of 
proteins (Söhl & Willecke, 2004). These proteins have traditionally been studied most 
thoroughly in quiescent vessels, where endothelial cells use this signaling mechanism for 
long distance communication. In this context, studies have shown that signaling via gap 
junctions regulates growth and differentiation of cells within the vessels (Gärtner et al., 
2012). The role of connexins in angiogenesis, however, is less well understood. 21 
different connexins have been identified in humans and they exhibit tissue-specific 
expression patterns (Söhl & Willecke, 2004). Additional complexity is introduced by the 
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involvement of different connexins in endothelial-endothelial, smooth muscle-smooth 
muscle and endothelial-smooth muscle gap junctions. Nevertheless, studies have shown 
that endothelial specific knockout of Cx40 and Cx37 in mice results in severe vascular 
abnormalities (Simon & McWhorter, 2002). In conjunction with cell culture models, 
these studies have suggested the importance connexins in the angiogenic process 
(Bazzoni & Dejana, 2004; Hill, Rummery, Hickey, & Sandow, 2002). The underlying 
mechanisms, however, remain an area of ongoing research. 
 In addition to gap junctions, quiescent endothelial cells normally maintain cell-
cell junctions via tight junctions (claudins, occludins) and adherens junctions (cadherins) 
(Jain, 2003). During angiogenesis, however, the junctions between endothelial cells are 
temporarily dissociated, thus limiting the role of cell-cell junctional proteins in sprouting 
endothelial cells to steps in which the cells are acting as a synchronized unit (Wallez & 
Huber, 2008). Within this context, studies have shown that VE-cadherin is required for 
proper lumen formation and localization of CD34 (Strilic et al., 2009). During the latter 
stages of angiogenesis, N-cadherin stabilizes contacts between endothelial cells and 
pericytes, which in turn enhance the production of basement membrane proteins 
including laminins and collagen IV (Stratman, Malotte, Mahan, Davis, & Davis, 2009). 
Ultimately, it is a complex interplay of pro- and antiangiogenic growth factors, 
extracellular signals from the ECM, and cell-cell signals that drive the coordinated 
process of vessel formation. Given the complexity of this system, it ensures that an 
optimal vascular network is formed during development and wound healing. It is this 
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complexity, however, that also makes angiogenic pathways susceptible to a variety of 
misregulated signals during disease (Ferrara & Kerbel, 2005). 
1.3.5 Therapeutic angiogenesis and its role in the clinic 
Blood vessels nourish virtually every organ in the body and are critical for development, 
wound healing and maintenance of homeostasis. In disease, however, insufficient vessel 
growth can lead to stroke, myocardial infarction, ulcerative disorders and 
neurodegeneration (Carmeliet & Jain, 2000). Abnormal vessel growth helps drive cancer, 
inflammatory disorders and pulmonary hypertension among other diseases (Carmeliet, 
2003; Folkman, 2007). While anti-angiogenic therapies are by far more widely studied, 
therapeutic vascularization of ischemic tissues remains a central goal in the study of 
angiogenesis. Treatment of ischemic heart disease via angiogenic therapies, for example, 
is receiving significant interest after several clinical studies have demonstrated 
preliminary success in providing additional blood flow to poorly vascularized areas in 
patients with myocardial ischemia (Laham et al., 1999; Rosengart et al., 1999; 
Schumacher, Pecher, Specht, & Stegmann, 1998). In such physiologic contexts where 
revascularization of injured tissues is delayed or pathological due to insufficient vessel 
growth, VEGF-related therapies remain the most widely studied (Carmeliet, 2003). Other 
angiogenic therapies, however, that attempt to introduce angiogenic cues from sources 
such as platelets and monocytes are also being considered (Bottomley et al., 1999; Griga, 
Werner, Köller, Tromm, & May, 1999). 
 Given the inherent complexities that underlie the formation of a stable and 
functional vasculature, effective angiogenic therapy remains a difficult goal. Indeed, 
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attempts at promoting new vessel growth that hinge upon the delivery of single growth 
factors such as VEGF or bFGF have led to the formation of leaky vessels and failed in 
clinical trials (Henry et al., 2001; Stewart et al., 2009). As additional angiogenic 
pathways are being elucidated, new clinical targets are continually emerging. For 
example, angiopoietin has now been shown to help repair or prevent damaged and leaky 
vessels in diabetic retinopathy, acute macular degeneration, and ischemia/reperfusion 
injury (Thurston et al., 2000; 1999). Overall, molecules from the VEGF family, 
Angiopoietin-1, β-Estradiol, the FGF family, IL-8, Leptin, MCP-1, MMPs, NOS, PDGF-
BB, TNF-α, Angiogenin, TGF have all been studied in various animal models with 
promising preclinical results (Pandya, Dhalla, & Santani, 2006). 
A variety of novel approaches to deliver proangiogenic agents have also recently 
been developed. These range from gene therapy approaches utilizing viral delivery of 
recombinant growth factors to biomaterials with controlled release properties (Ferrara & 
Kerbel, 2005; Folkman, 2007; Pandya et al., 2006). Despite advances, the clinical 
viability of these therapies remains to be tested in a controlled setting. Notably, initial 
trials in which patients with myocardial or limb ischemia were treated with VEGF-A, 
VEGF-C, FGF-1, FGF-2 and FGF-4 showed promising results, but larger placebo-
controlled trials that utilized recombinant proteins or gene therapy later yielded only 
marginal results (Henry et al., 2003; Lederman et al., 2002; Simons, 2005). Most 
recently, attempts at cell-based strategies for revascularization using bone-marrow 
derived endothelial progenitor cells have demonstrated additional promise (Rafii & 
Lyden, 2003). Transplantation of bone marrow mononuclear cells into ischemic muscle 
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of patients suffering form peripheral arterial disease resulted in restored limb function 
(Tateishi-Yuyama et al., 2002; Tomita et al., 1999). Larger placebo-controlled studies, 
however, will again be required to validate these findings and assess long-term benefits. 
The failures of growth factor therapies and emergence of cell-based strategies 
highlights the need for a more integrated approach to angiogenic therapies (Yoshida et 
al., 2010). In an attempt to help restore the appropriate microenvironmental cues 
necessary for proper vascularization of tissue, many tissue-engineered vascularization 
strategies are quickly emerging as potentially viable methods for properly revascularizing 
injured tissues (Thwaites, Reebye, Mintz, Levicar, & Habib, 2012). 
 
1.4 Tissue engineering approaches to promote angiogenesis 
Shortly after the inception of tissue engineering as a field, vascularization quickly 
emerged as a central topic of research (Kaully, Kaufman-Francis, Lesman, & Levenberg, 
2009; Lovett et al., 2009). The need to vascularize engineered tissues combined with 
unmet clinical needs for therapeutic angiogenesis have sparked significant research 
efforts. Novel integrated approaches that utilize growth factors, synthetic matrices and 
cells often in combination hold great promise. It should be noted, however, that this area 
of research is in a much more nascent state than the angiogenic therapies discussed in the 
previous section, and none of the approaches discussed here have yet been thoroughly 
tested in human clinical trials. As these efforts begin to enter human trials over the 
coming years, a number of viable approaches are likely to emerge (Orlando, Wood, et al., 
2011b). The current strategies for vascularization and promoting angiogenesis can be 
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categorized into two major categories: 1) approaches that utilize biofunctional materials 
and 2) approaches that utilize cells to induce vascularization (Lovett et al., 2009). 
1.4.1 Biofunctional materials for inducing angiogenesis 
Given our understanding of the role of cell-matrix and cell-cell adhesive and mechanical 
cues in the angiogenic process, it is clear that proper signals from the ECM are necessary 
for effective vessel growth. A variety of both natural and synthetic materials have been 
studied for their ability to provide these cues (Lutolf & Hubbell, 2005; Moon et al., 2011; 
Tian & George, 2011). Two synthetic material backbones have been primarily used for 
inducing vascularization: poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol 
(PEG) hydrogels. PLGA, a biodegradable and biocompatible polymer, has been used 
extensively in medicine as a temporary mechanical support in implantable medical 
devices (Athanasiou, Niederauer, & Agrawal, 1996). The use of synthetic polymers for 
inducing angiogenesis allows full control over a number of material properties and avoids 
the risks associated with using potentially immunogenic natural materials (Lutolf & 
Hubbell, 2005; Orlando, Wood, et al., 2011b). Most notably, Mooney and colleagues 
have developed implantable PLGA scaffolds that sequentially release VEGF and PDGF 
and induce vessel ingrowth when implanted into mice (R. R. Chen, Silva, Yuen, & 
Mooney, 2006). While promising, it is not yet clear whether this approach is capable of 
generating mature vessels that remain stable over long periods of time (Peters et al., 
2002). Most recently, studies utilizing this approach have also demonstrated that 
combinations of bFGF, VEGF and S1P are also capable of inducing vascularization in 
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vivo (Tengood, Kovach, Vescovi, Russell, & Little, 2010; Tengood, Ridenour, Brodsky, 
Russell, & Little, 2011). 
Recently, PEG hydrogels have emerged as an alternative synthetic scaffold for 
inducing angiogenesis (Zisch et al., 2003). Since natural ECMs are hydrogels, the 
structure of PEG provides a close synthetic mimic for host ECM (Moon et al., 2011). 
PEG hydrogels also possess highly tunable mechanical properties and can be 
functionalized with various proteins or peptides to render the material adhesive and 
degradable (Lutolf & Hubbell, 2003). Angiogenic studies with PEG hydrogels have 
demonstrated enhanced angiogenesis using the materials in in vitro, ex vivo and in vivo 
models of angiogenesis (Leslie-Barbick, Moon, & West, 2009; Moon, Lee, & West, 
2007). 
While promising, the application of synthetic or natural matrices alone has yet to 
demonstrate the ability to rapidly vascularize tissues. These approaches, however, are 
helping to provide insights into the design of more complicated strategies involving the 
use of exogenous cells. For example, Putnam and colleagues have focused on the 
interplay between ECM mechanics and vascularization potential (Ghajar, Chen, Harris, 
Suresh, et al., 2008a; Kniazeva & Putnam, 2009). This work is paving the road for 
understanding critical design parameters in developing the next generation of 
vascularization strategies. 
1.4.2 Cell-based strategies for generating microvasculature 
A critical drawback of vascularization strategies that rely on the use of acellular synthetic 
or natural matrices is the inability to rapidly vascularize an engineered or damaged host 
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tissue (X. Chen et al., 2010; Jain, Au, Tam, Duda, & Fukumura, 2005). Specifically, large 
engineered tissues must become quickly vascularized (1-2 days) upon implantation in 
order to prevent parenchymal cell death (Orlando, Baptista, et al., 2011a). In a disease 
setting, ischemic tissues need to be revascularized as quickly as possible to minimize 
necrosis and tissue damage. Accordingly, attempts to more rapidly vascularize tissues 
have attempted to leverage the use of cells embedded within natural or synthetic scaffolds 
to help speed up the vascularization process (Kaully et al., 2009; Lovett et al., 2009). 
 The driving principle behind cell-based vascularization strategies is to implant a 
rudimentary vascular network or a population of vascular cells capable of rapidly 
connecting with the host vasculature (X. Chen et al., 2009). Most current studies in this 
area remain limited to natural matrices. Though synthetic polymer chemistry is advancing 
rapidly, natural matrices inherently posses the proper adhesive, mechanical and 
degradable properties known to be necessary for proper vascularization (Kaully et al., 
2009). It is likely that a switch to synthetic materials will occur over time as they become 
better understood and more tunable to these applications. 
 A seminal study in the area of cell-based vascularization approaches was first 
performed by Jain and colleagues in which they combined endothelial cells and 
embryonic mesenchymal cells in a type I collagen gel (Koike et al., 2004). Implantation 
of this construct into mice resulted in the formation of vessels that remained stable for 
four months. Furthermore, portions of the vessel walls contained the originally implanted 
cells, demonstrating for the first time that exogenous cells directly contribute to the 
formation of vessels. Subsequent studies have since focused on varying cell-type, ECM 
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material or in vitro culture conditions in an attempt to find a set of optimal conditions for 
generating functional vasculature in vivo (Lovett et al., 2009). In another study Jain and 
colleagues used endothelial progenitor cells to demonstrate the ability of their engineered 
vessels to remain stable up to one year in vivo upon implantation (Au, Tam, Fukumura, & 
Jain, 2008b). Most recently, work by George and colleagues has focused on rapidly 
vascularizing the engineered tissues once implanted. Using endothelial cells and a variety 
of supporting cell types embedded in a fibrin matrix, they demonstrated the formation of 
perfused vessels within one day of implantation (X. Chen et al., 2009; 2010). Additional 
biological insights have shown that the type of cell used within these engineered 
constructs can come from an autologous source (Melero-Martin et al., 2008), and that the 
presence of myeloid cells, an immune component, is necessary for proper vessel 
formation (Fantin et al., 2010). Evidence also suggests that implanted vascular cell 
networks anastomose with the host vasculature via a novel “wrapping-and-tapping” 
mechanism (Cheng et al., 2011). 
While work is underway to gain a better understanding of the vascularization 
mechanisms within these engineered constructs – likely a combination of vascular 
network assembly, angiogenesis and anastomosis – basic insights have already begun to 
drive their application towards generating functional engineered tissues (Orlando, 
Baptista, et al., 2011a; Vacanti, 2012). One particular area of focus is that of vessel 
organization. To date, all cell-based vascularization techniques have used randomly 
seeded cells within a scaffold that provide no specific patterning cues to the growing 
vasculature (Zheng et al., 2011). Interestingly, George and colleagues have demonstrated 
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that by preculturing cells within fibrin constructs, which allows them to organize into 
rudimentary networks, a more rapid formation of perfused vasculature can be achieved in 
vivo upon implantation (X. Chen et al., 2009). More recent work has shown that 
organized vessel networks improve the function of skeletal muscle grafts upon 
implantation (Koffler et al., 2011). Together these studies suggest that patterning of 
engineered vasculature is an area worthy of further investigation. Indeed, vasculature 
generated via developmental processes is guided by a number of patterning cues and, 
through a sequence of regulated spatiotemporal signals, reaches a geometry that is 
optimal for the perfusion of the surrounding tissue (LaRue et al., 2003; Melani & 
Weinstein, 2010; Rivron et al., 2012; Ruhrberg et al., 2002). In the engineered context, an 
ability to pattern the vasculature de novo would usher in the possibility of studying 
optimal vessel patterns and subsequently using them to develop larger functional 
engineered tissues for use in the clinic (Orlando, Baptista, et al., 2011a; Rustad et al., 
2010). 
 
1.5 The vasculature in a disease context: pulmonary arterial 
hypertension 
Proper vessel function is critical for maintaining homeostasis in healthy organisms. 
Malformations or aberrant vessel function contribute to the pathogenesis of many 
diseases, and cardiovascular disease remains the biggest cause of deaths worldwide 
(Carmeliet, 2003; Carmeliet & Jain, 2000; Lloyd-Jones et al., 2010). One specific 
example includes pulmonary arterial hypertension (PAH), a condition characterized by 
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elevated pulmonary arterial pressure (Lourenço, Fontoura, Henriques-Coelho, & Leite-
Moreira, 2011). In patients with PAH, the increased vascular resistance in the pulmonary 
circulation places a greater workload on the heart and ultimately leads to right ventricular 
failure and premature death. PAH can be hereditary, associated with other conditions 
(including congenital heart disease, HIV and others) or idiopathic. Idiopathic pulmonary 
arterial hypertension (IPAH), which occurs in the absence of identifiable risks, is 
particularly difficult to diagnose (Gaine & Rubin, 1998; Rubin, 1997). Patients present 
with general symptoms and diagnosis is only made after the exclusion of other heart and 
lung diseases known to cause elevations in pulmonary arterial pressure (Chin & Rubin, 
2008). In patients with IPAH, the estimated survival rates for patients receiving treatment 
at 1, 2, and 3 years are 83, 67, and 58%, respectively (Humbert et al., 2010). Despite 
advances in hypertension research, no cure currently exists for PAH (Agarwal & 
Gomberg-Maitland, 2011). 
1.5.1 Pathology and current treatments 
Pulmonary arterial hypertension is typified by hyperproliferation and remodeling within 
the small pulmonary arteries, which results in increased blood pressure within the lung 
vasculature. Characteristic abnormalities in the pulmonary arteries of PAH patients 
include thickening of the intimal, medial and adventitial compartments (Chin & Rubin, 
2008; Gaine & Rubin, 1998; Rubin, 1997). Detailed histological examination of 
pulmonary arterioles in patients with IPAH shows neointimal thickening, pulmonary 
arteriolar occlusion, and plexiform lesions, suggesting that IPAH is a primarily 
vasoproliferative disease with accompanying vasoconstriction as well as catabolism and 
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de novo synthesis of components of the extracellular matrix (ECM) (Chin & Rubin, 2008; 
Farber & Loscalzo, 2004; Humbert et al., 2004; Jones & Rabinovitch, 1996; Jones, 
Cowan, & Rabinovitch, 1997; Pietra et al., 1989).  
 Three classes of drugs are currently used to treat PAH: prostacyclin analogs, 
endothelin receptor antagonists and phosphodiesterase type 5 inhibitors (Agarwal & 
Gomberg-Maitland, 2011). The vasoconstriction and progressive vascular cell 
proliferation seen in PAH patients may stem from low levels of endogenous prostacyclin 
(Rubin et al., 1982). Thus, prostacyclin analogs were introduced to target the 
prostaglandin I receptor, which is capable of inducing potent vasodilation through the 
activation of cyclic adenosine monophosphate (Agarwal & Gomberg-Maitland, 2011). 
The most notable drug in this category and the current first-line preferred drug for PAH 
treatment is epoprostenol. Its long-term benefits have been reported by two large centers 
and it remains as the only therapy for advanced PAH that has proven to enhance survival 
(Barst et al., 1996). While demonstrating very favorable outcomes and improving 
patients’ quality of life significantly, its administration remains complicated due to the 
compounds’ 3-5 min plasma half-life (Fuentes, Coralic, & Dawson, 2012). Because of 
this limitation, patients undergoing treatment with epoprostenol must use a continuous 
infusion IV pump, which requires daily care and maintenance (Agarwal & Gomberg-
Maitland, 2011). More recently, two newer prostacyclin analogs have been introduced 
with longer half-lives, which allow for subcutaneous or inhalable routes of administration 
(Laliberte, Arneson, Jeffs, Hunt, & Wade, 2004; McLaughlin et al., 2010). 
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 Endothelin-A and endothelin-B are targets of the second class of drugs used in the 
treatment of PAH . Endothelin-1 is a potent vasoconstrictor and has been shown to 
increase smooth muscle cell proliferation (Boniface & Reynaud-Gaubert, 2011). 
Endothelin-1 levels in the circulating plasma of PAH patients are increased, further 
suggesting that its receptors may be a good target for treating PAH (Rubens et al., 2001). 
Bosentan and ambrisentan are two endothelin receptor antagonists currently in use today. 
While administration of these two drugs must be closely monitored due to potential liver 
toxicity issues, they remain widely prescribed to PAH patients (Rubin et al., 2002; Vatter 
et al., 2002). 
 Phosphodiesterase inhibitors act by inhibiting phosphodiesterase 5 in the nitric 
oxide-cGMP pathway. Briefly, nitric oxide elicits vasodilatory and antiproliferative 
effects via the release of cyclic guanosine monophosphate (cGMP). cGMP, however, is 
typically rapidly broken down by phosphodiesterase 5 (Agarwal & Gomberg-Maitland, 
2011). Thus, this category of PAH drugs aims to induce pulmonary vasorelaxation by 
preventing this rapid degradation of cGMP (Agarwal & Gomberg-Maitland, 2011). 
Sildenafil and tadafil comprise this category of drugs and are both administered orally 
(Galie et al., 2009; Ghofrani et al., 2002). 
 Despite the continuous development of drugs in each category, none of these 
effectively treat the underlying pathophysiology of PAH. Exercise capacity and, more 
importantly, pulmonary arterial pressures are never returned to normal levels upon 
administration of these compounds. Over time, even despite the introduction of 
combination therapies, quality of life in patients remains relatively low and no further 
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treatments outside the realm of lung transplantation currently exist (Agarwal & 
Gomberg-Maitland, 2011; Lourenço et al., 2011). Lastly, it should be noted that most of 
the currently administered drugs have been approved based on short-term studies. Few 
long-term well-controlled studies have been done to assess clinical outcomes (Barst et al., 
2009). In summary, while significant advances in the treatment of PAH have been made 
over the past two decades, no cure currently exists and little is understood about the 
underlying etiology of the disease. 
1.5.2 The role of vascular smooth muscle cells in pulmonary hypertension 
The majority of drugs first used in treating PAH were chosen for their vasodilatory 
effects. However, several have now demonstrated anti-proliferative effects in vitro and in 
animal models (Jiang, Zhou, & Liu, 2012; Wolf, Sauter, Risler, & Brehm, 2005). 
Abnormal SMC proliferation within pulmonary arteries of PAH patients is one of the 
hallmark characteristics of the disease (Humbert et al., 2004; Lourenço et al., 2011). 
Hyperproliferating SMCs are found in the plexiform lesions that are found occluding the 
intraluminal space in patients with sever PAH (Pietra et al., 1989). 
 It was shown more than thirty years ago that injured SMCs undergo a shift from a 
contractile phenotype to one that is synthetic and characterized by increases in 
proliferation, migration and ECM synthesis (Chamley, Campbell, McConnell, & 
Gröschel-Stewart, 1977). Subsequently, work over the past several decades has begun to 
focus on identifying drugs that are effective at inhibiting this proliferative response in 
PAH. Several studies demonstrated the ability of statins to inhibit SMC proliferation and 
migration and slow intimal hyperplasia  (Corpataux, Naik, Porter, & London, 2005; 
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Corsini et al., 1999; Porter et al., 2002)). It has been reported that a possible mechanism 
of action in this context is through Rho GTPase prenylation (Laufs, Marra, Node, & Liao, 
1999). More recent studies have specifically implicated aberrant PDGF signaling in SMC 
hyperproliferation (Humbert et al., 2004). Ito and colleagues showed that PDGF 
stimulation of SMCs isolated from lungs of PAH patients resulted in higher proliferation 
rates than those in control SMCs (Ogawa et al., 2005). In a follow-up study, they further 
demonstrated that simvastatin inhibits this PDGF-induced hyperproliferation through an 
upregulation of the cell cycle inhibitor p27 (Ikeda et al., 2010). Interestingly, they found 
that simvastatin treatment correlated with the disorganization of actin fibers and the 
inhibition of Rho translocation from the cytoplasm to the membrane, again suggesting 
that Rho GTPase signaling may play an important role. Their basic findings are also 
supported by studies that demonstrate the reversal of experimentally induced PAH in 
rodent models via the administration of PDGF inhibitors (Schermuly et al., 2005). 
In addition to PDGF, studies have also begun to implicate serotonin in PAH SMC 
hyperplasia (Lourenço et al., 2011). Eddahibi and colleagues have found that increased 
serotonin activity through upregulation of the 5-HTT serotonin transporter in isolated 
PAH SMCs or animal models of PAH contribute to SMC hyperproliferation (Guignabert 
et al., 2006; Marcos et al., 2004). Inhibition of 5-HTT in a rodent PAH model also 
suggested that it is a novel target worthy of consideration in the search for additional 
therapies. Finally, two studies have implicated aberrant endothelial-SMC interactions 
(Eddahibi et al., 2006) and glycogen synthase kinase 3beta (Sklepkiewicz et al., 2011) as 
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having direct involvement in the progression of PAH. Combined, these studies give hints 
at the types of molecular targets that might be at the focus of future PAH therapies. 
1.5.3 Regulation of smooth muscle cell proliferation by the microenvironment 
Fully differentiated smooth muscle cells in the healthy adult typically exhibit very low 
rates of proliferation (S. Schwartz, Campbell, & Campbell, 1986). During times of injury 
or vascular disease, however, these cells undergo a phenotypic switch and begin 
proliferating rapidly (A. W. Clowes, Reidy, & Clowes, 1983). While SMC proliferation 
is largely controlled by the same mechanisms as in other cell types, there are several 
microenvironmental cues that are of additional relevance when considering smooth 
muscle cell biology in the disease context. First, growth factors and other compounds that 
are involved in angiogenesis and vascular disease such as nitric oxide, EGF and PDGF 
have been shown to regulate SMC proliferation in vivo (Ferns et al., 1991; Lindner & 
Reidy, 1991; Nabel et al., 1993). 
 PDGF is a potent activator of SMC proliferation that is thought to primarily 
upregulate SMC proliferation via activation of ERK (Zhan et al., 2003). As discussed in 
the previous section, PDGF-induced hyperproliferation in PAH is now being directly 
targeted by several drugs. The effects of inhibiting downstream effectors such as ERK in 
PAH models, however, remain to be investigated. Although the antiproliferative effects 
of nitric oxide, a widely used and studied vasodilator, have been known for some time, its 
mechanisms of action are very broad and are still being studied today (Tsihlis et al., 
2011). In general, however, it is known that NO relies on the upregulation of cGMP and 
subsequent downregulation of the EGF-MAP kinase cascade (Yu, Hung, & Lin, 1997). 
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Overall, essentially all potent SMC mitogens tend to activate receptors with intrinsic 
tyrosine kinase activity (Cadena & Gill, 1992). In turn, these receptors activate 
corresponding intracellular pathways including MAP kinase, protein kinase B and protein 
kinase C (Berra et al., 1993; Coffer, Jin, & Woodgett, 1998; Seger & Krebs, 1995). 
Ultimately, these growth factors share activation of the cyclin-dependent kinases in the 
cell cycle pathway as a final common signaling pathway (Newby & Zaltsman, 2000). 
In addition to growth factors, vascular SMC proliferation is regulated by other 
extracellular cues derived from the surrounding ECM(Assoian & Marcantonio, 1997). 
Most notably, heparan sulfate proteoglycans inhibit proliferation directly by inhibiting 
signaling by growth factors via the protein kinase C pathway (Y. Wang & Kovanen, 
1999). Other components of the basement membrane have also been shown to help 
maintain a non-proliferative phenotype in normal SMCs. Specifically, Ross and 
colleagues showed that fibrillar collagen (versus monomeric) inhibits SMC proliferation 
via Cdk2 (Koyama, Raines, Bornfeldt, Roberts, & Ross, 1996). Lastly, mechanical 
stimuli such as stretch and ECM stiffness have begun to emerge as additional effectors of 
SMC proliferation (Gambillara, Thacher, Silacci, & Stergiopulos, 2008; C. Li & Xu, 
2000; Shaw & Xu, 2003; Shyu, Chao, Wang, & Kuan, 2005). While regulation of 
proliferation via mechanical stimuli has been shown in other cell types, we now know 
that stretching of the ECM substratum can induce SMC proliferation in the absence of 
cell-cell contacts (W. F. Liu, Nelson, Tan, & Chen, 2007). Overall, recent insights into 
the pathophysiology of PAH suggest that regulation of SMC proliferation via ECM 
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signals and mechanics may play a role in the disease progression. This area of research, 
however, remains largely unexplored in the context of PAH. 
 
1.6 Summary 
Over the last several decades, our knowledge of vascular disease and the underlying 
biology have increased tremendously. Studies described in the preceding sections have 
served as the inspiration for the work presented in the subsequent chapters. First, a study 
on the topic of engineered vasculature is presented in Chapter 2. This research draws on 
existing insights into the fundamental processes that underlie angiogenesis and attempts 
to extend current microvascular engineering approaches by introducing the ability to 
geometrically pattern vessels in vivo. Second, our study of PAH presented in Chapter 3 
provides new insights into the proliferative regulation of IPAH SMCs. In a broader 
context, these two studies comprise part of an ongoing paradigm shift in the fields of 
bioengineering. Drawing upon decades of ongoing research into fundamental biological 
processes, tissue engineering strategies and therapeutic approaches for treating vascular 
disease are increasingly being designed based less on anecdotal findings and more on a 
fundamental understanding of the underlying biological processes. 
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CHAPTER 2: Patterned vascular networks improve function of 
engineered tissues in vivo 
 
2.1 Introduction 
Engineered organ tissues are emerging as a new class of therapies to combat the scarce 
supply of heterologous donor organs available for transplant (Vacanti & Langer, 1999). 
While highly promising, a critical limitation in the field is the successful vascularization 
of large tissue constructs (Orlando, Baptista, et al., 2011a; Rustad et al., 2010). The future 
utility of engineered tissues relies on the development of vascular architectures that 
effectively deliver blood to these large and geometrically complex tissues (Kaully et al., 
2009).  
In vivo, native tissue is comprised of specialized cells and vasculature embedded 
within tissue specific ECM in a highly organized manner.  The liver, in particular, has a 
precisely-defined microarchitecture involving a complex interplay between hepatocyte 
cords, bile canaliculi, and microvessel networks that is thought to impact metabolic mass 
transport and tissue function (Reid, Fiorino, Sigal, Brill, & Holst, 1992).  Indeed, it is the 
loss of this architecture due to replacement by fibrotic tissue and regenerative nodules 
that defines chronic cirrhosis (Ishibashi, Nakamura, Komori, Migita, & Shimoda, 2009). 
Successful therapeutic tissue engineering strategies will rely in part on the ability to 
recapitulate proper tissue organization by integrating defined vascular networks with 
tissue specific cellular structures.  However, current strategies to study the combined 
effects of vascular organization and parenchymal juxtaposition have been limited to 
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random vascular self-assembly and tubulogenesis within natural and engineered ECMs as 
described above in section 1.3.2.  While promising, such strategies are currently unable to 
provide the spatial and geometric control of vessel architecture that is necessary for 
parenchymal cell survival within solid tissues (Vacanti, 2012). 
In this chapter, we describe the development and application of a novel approach 
for creating functional, spatially organized vascular architectures within engineered 
tissues. The underlying hypothesis of our work is that patterned constructs of endothelial 
cells can be used to induce vascularization in vivo. Our approach utilizes micropatterning 
techniques to organize endothelial cells into geometrically defined ‘cords’ that drive the 
formation of fully functional, patterned capillaries upon implantation into mice. We also 
demonstrate the ability of our vascularization strategy to maintain the viability and proper 
function of engineered hepatic tissue.  
 
2.2 Generation of patterned endothelial cell ‘cords’ in vitro 
2.2.1 Design, fabrication and optimization of a second-generation device for 
generating patterned cell cords 
Previous efforts in our laboratory have focused on the development of a technique for 
spatially patterning cells within micromolded collagen gels (Fig. 2.1A) (Raghavan, 
Nelson, Baranski, Lim, & Chen, 2010a). Using this technique, it was demonstrated that 
patterning endothelial cells embedded within collagen could be used to generate ‘cords’ 
that contain cell-cell junctions characteristic of physiologic endothelium (Fig 2.1B).  
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To enable their implantation and use in animal studies, we demonstrated that these cords 
could be removed from their underlying polydimethylsiloxane (PDMS) templates (Fig. 
2.2). This removal was accomplished by embedding the fully formed cords within a 
collagen gel, allowing the entire collagen/cord construct to be mechanically separated 
from the PDMS device. Use of PBS during the removal process helped to reduce damage 
to the construct and aid in its removal . 
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Figure 2.1 Early technique for generating patterned cell cords (A) Schematic of 
method for generating cords by organizing cells and collagen within 
microfabricated PDMS channels. (B) Phase contrast images of cords formed 
within 50 µm wide and 50 µm tall channels after 24 h in culture. (C) Fluorescence 
images of endothelial cell cords (red and green, actin; blue, nuclei) consisting of 
HUVECs and BAMECs cultured for 48 and 24 h, respectively. (D) PECAM 
(CD31) and β-catenin (E) are found at cell-cell junctions in EC cords. BAMECs, 
bovine adrenal microvascular endothelial cells. Data reprinted with permission 
(Raghavan, Shen, Desai, Sniadecki, Nelson, & Chen, 2010b). 
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Figure 2.2. Removal of cords from PDMS template. Phase contrast (A) and 
fluorescence (B) images of HUVEC cords removed after 24 h in culture into 2.4 
mg/ml collagen gel. Cells are labeled for actin (green) and nuclei (blue). Data 
reprinted with permission (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a). 
 
Given the ability to remove cords from the PDMS templates, we hypothesized 
that they could be used to generate geometrically defined vascular networks in vivo. 
Others have previously shown that improved organization of endothelial cell networks 
and transplanted capillary beds leads to improved vascularization (X. Chen et al., 2009; 
36 
Laschke et al., 2010). We predicted that the established cell-cell contacts within cords 
comprised of endothelial cells would help enhance their angiogenic potential and that 
patterned cord geometry would be preserved upon implantation and subsequent vessel 
formation in vivo. More broadly, we hypothesized that the implantation of patterned EC 
cords could be used to control the architecture of engineered vasculature in vivo. 
 While effective in demonstrating a proof of concept, use of the first-generation 
device for creating EC cords in extensive studies of vascularization was prohibitively 
time consuming, required large numbers of cells (> 6 million per device), and yielded 
cords that were limited in length (< 1 cm). To overcome these limitations, we designed, 
fabricated and optimized a second-generation system for producing and removing EC 
cords (Fig. 2.3). Fabrication of the new devices utilized a double-casting technique to 
generate microchannels with surrounding flat regions within a PDMS well rather than 
relying on a separate gasket (Fig. 2.3A, B). The second generation device was designed 
to enable generation of larger numbers of cords using fewer cells (2 million per device). 
The new device configuration allowed for cords to be easily removed from the 
underlying PDMS template and embedded within other ECM materials to generate 
implantable tissue constructs. The larger areas of cords could later be cut or ‘punched 
out’ with a biopsy punch in preparation for implantation. Overall, the redesign resulted in 
a twelve-fold reduction in the number of cells required to generate an implantable tissue 
construct. 
 
37 
 
Figure 2.3. First- and second-generation PDMS devices for generating cords. (A) 
Process flow describing technique for fabricating first-generation device for 
generating cords. (B) Process flow describing technique for fabricating second-
generation devices for generating cords. Macroscopic images of final devices are 
shown in bottom panels. (bars: 10 mm) 
 
 The complete redesign of the device required several optimizations to techniques 
for generating cords. First, treatment of the PDMS with Pluronic F-127 required 
modification. Pluronic, a nonionic, surfactant polyol, is used to render the surface of 
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PDMS hydrophilic, making it largely non-adhesive to proteins and cells (M.-H. Wu, 
2009). Here, a Pluronic treatment that is too mild will prevent proper cord formation by 
allowing cells to adhere and migrate on the PDMS surfaces. Conversely, a Pluronic 
treatment that is too harsh will render the PDMS surfaces almost entirely non-adhesive 
causing the cords to float out of the microchannels upon addition of growth medium. 
Through empirical tests, we determined that proper Pluronic treatment that achieves the 
correct balance of adhesive cues is obtained by exposing the PDMS templates to a 0.02% 
(w/v) Pluronic F-127 solution for 10 minutes. While we found that decreasing the 
concentration to below 2x10-5 % was required to observe any effects of decreased 
concentration, the length of Pluronic treatment had a significant impact on its effect. 
Additionally, it should be noted that the negative PDMS masters from which the final 
devices are cast could be reused no more that three times. After three casts, we observed 
that the resulting devices were more adhesive to collagen and cells despite treatment with 
Pluronic. Due to the double casting process, devices cast more than three times also 
began to exhibit defects in the walls of the microchannels. 
 Given the larger volume of collagen within the microchannels in the second-
generation device, application of the collagen and polymerization times also required 
optimization. To prevent possibly confounding results and limit the scope of our studies, 
we chose to fix the collagen concentration at 2.5 mg/ml. The design of the second-
generation device, which included flat regions that surrounded the microchannels, 
allowed for simple dewetting of the collagen by tilting the device and aspirating excess 
collagen mixture. Proper Pluronic treatment was found to be critical for this dewetting 
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step. In addition, the time required for the polymerization of the collagen required a 
balance between ensuring that the gel has fully formed and preventing too much drying 
of the sample, which led to cell death. Through a series of optimizations, we found that 
inverting the sample for 5 minutes over a bath of water during polymerization achieved 
the correct balance of gelation time and humidity and resulted in viable cords. Additional 
complexity is introduced by the technique used when adding growth medium to the 
polymerized cords immediately prior to culture. Upon methodically employing a variety 
of techniques, we determined that allowing large drops of medium to fall onto the 
microchannels yielded the best results. Briefly, five drops of growth medium are first 
dispensed into the center and four corners of the microchannels from a height of several 
millimeters. Subsequent drops are dispensed in a similar manner into the regions between 
those already placed onto the substrate. As the second set of drops is introduced, the 
growth medium accumulates into a larger pool that covers the entire area of 
microchannels containing cords. The final volume of medium is brought up to 750 µl by 
dispensing slowly into one of the corners of the device. Importantly, extreme care must 
be taken during this process not to dislodge the cords from the microchannels during 
these final steps. 
 Lastly, additional development of the technique was required to remove the cords 
into a PDMS-free ECM. While collagen was used in the first-generation device, we used 
fibrin for in vivo studies in order to take advantage of its proangiogenic effects (Hall, 
Baechi, & Hubbell, 2001; Lesman et al., 2011). After experimentation with a variety of 
methods, we found that cutting away of the surrounding PDMS well and inversion of the 
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microchannels containing cords onto a pool of pre-polymerized fibrin yielded the best 
results. Use of a PDMS gasket helps to ensure that constructs with a controlled thickness 
are generated. After 15 minutes of polymerization, the sample can then be flooded with 
PBS, which allows the positive buoyancy of the PDMS to help lift it off of the underlying 
fibrin matrix. Several layers of cords can be stacked on top of each other to generate 
more complex geometries. In the final step, an additional layer of fibrin is added to 
encapsulate the exposed surface of the cords. The large area of the microchannels allows 
for 6 mm discs to be generated, which are suitable for implantation into mice (Fig. 2.4). 
A schematic of the process for generating cords using the second-generation of devices is 
shown in Figure 2.5. 
 
 
Figure 2.4 Removal of EC cords into fibrin (A) Previous methods of cord removal 
resulted in cords with disrupted morphology. (bar: 250 µm) (B) Inversion of 
microchannels onto gaskets containing fibrin results in a preserved cord geometry. 
Gels can be cut into 6 mm modular constructs suitable for implantation into mice. 
(bar: 500 µm) (C) Controlled method for removal of cords allows for stacking several 
devices to generate more complex geometries. (bar: 200 µm) 
41 
 
 
Figure 2.5 Schematic of process used to generate EC cords using second-
generation PDMS devices. Design modifications including increased 
microchannel area and incorporation of flat border regions allow for the 
removal and generation of larger cords, which are amenable to implantation 
into mice. 
 
2.2.2 Screening cell types and coculture ratios for use in cords 
A variety of endothelial cell types have been used in tissue engineered vascularization 
strategies (Au, Daheron, Duda, Cohen, Tyrrell, et al., 2008a; Koike et al., 2004; Melero-
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Martin et al., 2008; Traktuev et al., 2009). Here, we screened the ability of HUVECs and 
eEnd.2 cells to organize into networks when cultured within collagen gels in vitro. Given 
our hypothesis that established cell-cell contacts might help enhance the angiogenic 
effect of implanted cords, we attempted to choose a cell mixture capable of extensive 
cell-cell interactions and networking behavior. We first tested the eEnd.2 murine 
embryonic endothelial cell line by culturing the cells in a 2.5 mg/ml collagen gel for 4 
days (Williams, Courtneidge, & Wagner, 1988). While these cells exhibited localized 
networking behavior, significant clumping was observed and large increases in cell 
number indicated high rates of proliferation (Fig. 2.6). This high rate of proliferation in 
3D led us to conclude that the eEnd.2 cell type was a poor candidate for use in a 
vascularization strategy whose goal it is to generate stable vessels in vivo. Next, we tested 
human umbilical vein endothelial cells (HUVECs), a primary endothelial cell type 
commonly used in angiogenesis and tissue engineering studies, for their ability to form 
networks and extensive cell-cell contacts. After 4 days in culture within collagen gels, 
these cells exhibited limited networking behavior (Fig. 2.7). Proliferation, however, 
seemed significantly lower than in the eEnd.2 cells. 
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Figure 2.6 Networking behavior of e.End2 cells in collagen gels. Brightfield 
imaging of eEnd.2 cells cultured in 2.5 mg/ml collagen for 4 days at 
concentrations of 1x105 cells/ml (A), 5x105 cells/ml (B), 1x106 cells/ml (C) and 
2x106 cells/ml (D) shows localized networking (clumping) and suggests extensive 
proliferation. (bars: 100 µm) 
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Figure 2.7 Networking behavior of HUVECs in collagen gels. Brightfield 
imaging of HUVECs cultured in 2.5 mg/ml collagen for 4 days at concentrations 
of 1x105 cells/ml (A), 5x105 cells/ml (B), 1x106 cells/ml (C) and 2x106 cells/ml 
(D) shows limited networking or cell-cell interactions. (bars: 100 µm) 
 
C3H10T1/2 is a murine cell line of mesenchymal origin with demonstrated 
potential to differentiate into pericytes and promote vessel maturation (Hirschi, 
Rohovsky, & D'Amore, 1998; Koike et al., 2004). We screened the behavior of HUVECs 
in the presence of varying ratios of 10T1/2s when cultured within collagen gels in vitro. 
Previous results indicated that a density of 1x106 HUVECs/ml yielded a cell dense 
environment that did not lead to clumping. Thus, we included 10T1/2s in culture with 
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HUVECs at ratios of 1:50, 1:30 and 1:10 (10T1/2s to HUVECs) while maintaining the 
total cell number at 1x106 cells. We assessed the behavior of this cell mixture after 4 days 
in culture in a 2.5 mg/ml collagen gel (Fig. 2.8). Evidence of networking and increased 
cell-cell contacts was increased when 10T1/2s were added to the HUVEC/collagen 
mixture. Increased 10T1/2 ratios seemingly led to increased networking behavior. At 
higher concentrations of 10T1/2s, some clumping was evident. Based on these 
preliminary screens and existing studies, a ratio of 1:50 10T1/2s to HUVECs was 
ultimately chosen for generating EC cords. Unless otherwise noted, this mixture of cells 
was used throughout the remaining studies described in this dissertation. 
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Figure 2.8 Networking behavior of HUVECs + C3H10T1/2 cells collagen gels. 
Brightfield imaging of 1x106 HUVECs cultured in 2.5 mg/ml collagen for 4 days 
at with no 10T1/2s (A), 1:50 (B), 1:30 (C) or 1:10 (D) ratios of 10T1/2s to 
HUVECs. (bars: 100 µm) 
 
2.2.3 In vitro characterization of endothelial cell cords 
Having created a robust platform for generating cords, we performed several 
characterizations to better understand the composition of cords and the mechanics and 
cellular dynamics of the cord formation process. First, time-lapse imaging of cells 
fluorescently labeled with calcein revealed that the small population of 10T1/2s remained 
randomly distributed within the mostly HUVEC cords throughout the contraction process 
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(Fig. 2.9A,B). Hematoxylin and eosin (H&E) and sirius red staining of fully contracted, 
paraffin embedded cords suggested that some clustering and wrapping of cells around a 
core of compacted collagen might also occur (Fig. 2.9C). These occasional clusters, 
however, were randomly distributed along the length of the cords. 
 
 
Figure 2.9 Relative distribution of HUVECs, 10T1/2s within collagen in EC 
cords. (A) Combined phase and fluorescence images of cord formation at 0 
and 10 hours within PDMS microchannels (HUVECs: magenta, 10T1/2s: 
green, bars: 50 µm). (C) Maximum intensity z-projection of fluorescently 
labeled HUVECs (magenta) and 10T1/2s (green) within fully formed cords 
(bar: 50 µm). (bars: 20 µm). 
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Once in culture, cords contracted to approximately 65% of their original diameter 
over a period of 10-12 hours (Fig. 2.10). To verify that this contraction is driven by cells 
exerting tractional forces against the surrounding ECM we treated cords with the myosin 
IIa inhibitor blebbistatin or the RhoA inhibitor Y27632. When treated with these 
inhibitors immediately after seeding, the cords remained in their uncontracted state (Fig. 
2.10). Wash our of the inhibitors after 6.5 or 7.5 hours led to a rapid resumption of the 
contraction process. Within 6 hours of wash out, the cords had contracted to 
approximately 50-60% or their original diameter, which matched the contractility at 6 
hours of cords treated with DMSO. These treatments confirmed our hypothesis that 
RhoA and myosin-mediated cytoskeletal tension are required for cord contraction. 
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Figure 2.10 Cytoskeletal tension is required for cord contraction in vitro. (A) 
Time lapse imaging depicting cord formation in samples treated with vehicle, 
blebbistatin, or Y27632 (bars: 50 µm). (B) Quantification of cord contraction 
reveals rapid increase in contraction after wash out of cytoskeletal tension 
inhibitors. 
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To determine whether the presence of 10T1/2 cells affected the dynamics of cord 
contraction, we generated HUVEC only cords and compared their contraction rate to that 
of HUVEC + 10T/1/2 cords (Fig. 2.11). Given the contractile nature of mural cells in 
vivo, we predicted that cords containing 10T1/2s would contract more rapidly or to a 
higher degree than those containing HUVECs alone. Interestingly, both cord types 
exhibited similar contraction rates, suggesting that the contribution from 10T1/2 cells was 
negligible or not detectable in the presence of a high number of HUVECs. 
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Figure 2.11 Contribution of C3H10T1/2 cells to cord contractility (A) Time-lapse 
phase contrast imaging shows contracting cords containing HUVECs + 10T1/2s 
or HUVECs only. Dashed lines delineate cord boundaries. (bars: 50 um) (B) 
Quantification of cord diameter indicates that the inclusion of 10T1/2 cells in 
cords has no significant impact on their contractility dynamics (error bars: sem, 
n=2). 
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 To demonstrate the potential of using EC cords to pattern vasculature into a 
variety of geometries, we attempted to generate cords with a range of diameters and 
shapes. While in our previous work we demonstrated that varying collagen concentration 
could be used to alter final cord diameter, this approach is limited to a small range of 
diameters (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a). Here, we chose to 
maintain a consistent collagen concentration while varying the PDMS microchannel 
width. To maintain a 1:1 aspect ratio for the various microchannel widths, separate 
wafers with matching heights were fabricated for each width. For cords with varying 
geometries, 150 µm wide and 150 µm deep microchannels were used. Several minor 
optimizations were necessary when generating cords of varying diameters. Cords smaller 
than 100 µm yielded a much-reduced volume of collagen within the PDMS 
microchannels than the typical 150 µm cords. Because such a small volume of collagen 
polymerized and dried out much more quickly, the polymerization time was reduced to 
just 2-3 minutes for smaller cords. In addition, the smaller microchannels exhibited a 
tendency to trap bubbles. After experimentation with a variety of techniques including 
vacuum degassing, we found that using a 1:20 rather than the typical 1:10 w/w ratio of 
PDMS base to curing agent resulted in much softer PDMS that could be more vigorously 
‘scraped’ without damage to help remove trapped bubbles. Lastly, the technique for 
adding growth medium to the various cord shapes required adjustment. We found that in 
order to prevent the patterned cords floating out of the microchannels, it is necessary to 
add growth medium in a particular sequence: first to the areas most prone to damage such 
as vertices or junctions, second to the exposed ends of cords, and third to the remainder 
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of the cords and surrounding flat regions. These modifications allowed us to successfully 
generate cords with diameters that ranged from 25 µm to 500 µm (Fig. 2.12A) and a 
variety of architectures (Fig. 2.12B). 
 
 
Figure 2.12 Generation of EC cords with varying diameters and geometries. (A) 
Phase contrast images of cords of varying diameters  removed from PDMS 
templates and embedded in fibrin. (bars: 150 µm) (B) Brightfield images of 
cords with branching geometries removed from PDMS templates and embedded 
in fibrin. (bars: 1 mm) 
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2.3 Vascularizing engineered tissues in vivo via implantation of 
endothelial cell cords 
2.3.1 Development of in vivo implantation model 
To enable us to study the capability of EC cords to induce vascularization in vivo, we 
tried several surgical implantation models. We first attempted implantation of tissue 
constructs (fibrin gels containing EC cords) subcutaneously onto the backs of athymic 
mice. We found that constructs that were not sutured into place would never engraft 
properly into the host tissue. Seemingly, the unanchored constructs were always mobile 
within the subcutaneous space while the mice were active, which prevented them from 
engrafting. Next, we attempted to suture the tissue constructs in place to the subcutaneous 
tissue (hypodermis). While this approach effectively immobilized the constructs in place 
and seemed to improve engraftment, no vascular response was observed (Fig. 2.13A). We 
next attempted intra- and perimuscular implantation of our tissue constructs on the flanks 
of athymic mice. Both of these surgical sites required suturing to keep the construct 
properly immobilized. Neither site, however, resulted in a visible vascular response. 
Lastly, we implanted tissue constructs containing EC cords by suturing them directly to 
the parametrial fat pad within the intraperitoneal cavity. Gross observation of constructs 
harvested 5 days post implantation (PI) suggested proper engraftment and potential 
vascularization (Fig. 2.13). While observations of the gross anatomy of resected tissue 
constructs provided insights into the lack or presence of a response, histological 
techniques including hematoxylin and eosin (H&E) staining were used to verify the 
initial observations. Indeed, H&E staining of tissue constructs implanted adjacent to the 
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parametrial fat pad strongly suggested that blood was present within or near the 
implanted cords (Fig. 2.14). 
 
 
Figure 2.13 Gross anatomy of tissue constructs resected 5 days post-implantation 
(A) Tissue construct (dashed line) sutured to the hypodermis remained 
immobilized, but failed to become vascularized. (bar: 250 µm) (B) Tissue 
constructs sutured to the parametrial fat pad and exhibited a reddish appearance, 
which was suggestive of vascularization. (bar: 200 µm) (C) The patterns visible 
within these constructs sometimes mimicked those of the implanted cord 
architecture (arrowheads). (bar: 100 µm) 
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Figure 2.14 Early evidence of blood in implanted tissue constructs containing EC 
cords. H&E staining suggesting presence of blood in tissue constructs implanted 
adjacent to the parametrial fat pad. Fibrin gels containing EC cords directly 
sutured to the parametrial fat pad and resected 5 days PI. Arrowheads denote 
cords with evidence of red blood cells in transverse (left panel) or longitudinal 
cross section. (bars: 100 µm) 
 
 While histological examination of tissue constructs implanted adjacent to the 
fat pad indicated the presence of blood within cords, the overall architecture of the 
constructs and cords contained within was poorly preserved. This inability to 
maintain the originally patterned architecture within the tissue constructs made it 
difficult to properly assess the vascular response within the cords. To better preserve 
the geometry of the tissue constructs, we devised several approaches that utilized stiff 
and biocompatible materials to prevent the implanted constructs from losing their 
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shape upon implantation. First, we created our tissue constructs atop a thin (1 mm) 
layer of PDMS. The combined PDMS and fibrin gel with cords were cut into 6 mm 
discs using a biopsy punch. Small (0.75 mm) holes were punched near the periphery 
of the PDMS to allow for sutures to be passed through the structure for attaching to 
host tissue (Fig 2.15A). Without these holes near the discs’ periphery, passing a 
suture needle through the PDMS discs led to tearing. This approach successfully 
maintained the shape/geometry of the constructs upon implantation. However, we 
found that the PDMS discs engrafted to the host adipose tissue making their removal 
without disrupting the implanted constructs extremely difficult. Because PDMS 
cannot be sectioned resecting the entire fat pad and implanted construct with the 
PDMS still attached would prohibit any subsequent histological analysis. Given these 
complications with PDMS, we next attempted to use a polypropylene mesh as a 
backing material for the tissue constructs. We cut small squares of mesh material (~1 
cm2) and embedded them in fibrin. This procedure was performed atop a Pluronic-
treated PDMS-coated petri dish to aid in the detachment of the fibrin prior to 
implantation. We next inverted cords onto the mesh/fibrin layer and removed them as 
before. The resulting assembly consisted of a layer of cords positioned immediately 
atop the polypropylene mesh with the entire assembly encased in fibrin (Fig. 2.15B). 
While it was possible to section the polypropylene mesh, we found that the mesh 
filaments prevented any imaging of the embedded cords. To enable potential 
intravital imaging of our tissue constructs, we utilized a ‘donut’-shaped 
polypropylene mesh (Fig. 2.15B). These donut-shaped meshes were generated using 
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heated cork borers. The smooth outer edge facilitated their manipulation during 
surgery, while the inner hole would allow for direct imaging of the cords in the 
future. Use of a mesh material allowed for the needle and sutures to be passed directly 
through the periphery of the mesh without any further modifications during 
implantation (Fig. 2.15D). 
 
 
Figure 2.15 Development and implantation of a backing structure implantable 
tissue constructs. (A) Cords embedded in fibrin atop a PDMS backing structure 
containing holes for suturing. (bar: 1 mm) (B) Cords atop polypropylene mesh 
embedded in fibrin. Mesh structure allowed for suture and needle to be passed 
through the material without any additional modifications. (bar: 2 mm) (C) Cords 
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atop ‘donut-shaped’ mesh embedded in fibrin. Inner hole facilitated imaging of 
cords while smooth outer edge aided in implantation. (bar: 1 mm) (D) Mesh ring 
sutured sutured atop the parametrial fat pad in preparation for implantation. (bar: 
4 mm) 
 
 The polypropylene mesh incorporated into our design could be readily sectioned 
and successfully preserved the geometry of the implanted tissue constructs. These 
refinements to the implantation model allowed us to more thoroughly investigate whether 
cords were eliciting a vascularization response in vivo. H&E and sirius red staining of 
paraffin embedded tissues resected after 7 days indicated the presence of collagen-rich 
structures spatially organized in a pattern that mimicked the original position of the 
implanted cords (Fig. 2.16A). Higher magnification suggested the presence of blood in 
cell-rich regions that surrounded the periphery of the cords (Fig. 2.16B). 
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Figure 2.16 Preservation of geometry and presence of blood in EC cords resected 
7 days post-implantation. (A) H&E and sirius red staining of cord-containing 
tissue constructs resected after 7 days in vivo suggests that original cord geometry 
was preserved upon implantation. Arrowheads indicate location of cords. (bar: 50 
µm) (B) Higher magnification indicates areas of blood around the periphery of 
cords. (bars: 10 µm) 
 
 Our first analyses of vascularization within implanted EC cords relied solely on 
traditional histological stains such as H&E, sirius red and fast green. These stains were 
performed on sections cut from paraffin embedded tissue constructs. To facilitate 
immunohistochemical staining, we attempted to cut frozen sections of tissue constructs 
that were resected 5 days PI, briefly fixed and cryoembedded (Fig. 2.17). The cutting of 
tissue constructs via frozen section techniques, however, proved extremely difficult due 
to the heterogeneous nature of the tissues. While the optimal cutting temperature of the 
fibrin tissue constructs was relatively high (-17 oC), the temperature required for properly 
cutting the surrounding adipose tissue was extremely low (-35 oC). This incompatibility 
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in cutting temperatures resulted in smearing of the adipose tissue at higher temperatures 
and defects (likely due to cracking) in the fibrin tissue constructs at lower temperatures. 
Given these difficulties in cutting frozen sections, all immunohistochemical analyses 
described in this dissertation relied on paraffin embedded histological techniques, which 
yielded significantly improved preservation of tissue morphology (Fig. 2.17B).  
 
 
Figure 2.17 Frozen sectioning of tissue constructs. (A) Low magnification of H&E 
stained frozen section resected 5 days PI. Sections cut at low temperatures exhibited 
defects in the fibrin gels, while cutting at higher temperatures led to smearing of 
adipose tissue. Arrowheads indicate areas of cutting defects. (B) Sections cut from 
paraffin embedded tissue constructs showed no signs of defects and appeared to 
62 
exhibit improved preservation of morphology (tissue construct implanted without 
mesh support). (bars: 500 µm) 
 
2.2.2 Implantation of endothelial cell cords drives formation of mature capillaries in 
vivo 
To confirm whether implantation of endothelial cell cords resulted in the formation of 
blood vessels, we harvested tissue constructs at days 3, 5, 7, 14 and 28 post implantation 
(PI). H&E staining suggested the presence of red blood cells (RBCs) within cords as 
early as 3 days PI (Fig. 2.18A) with larger pools of blood also evident at both 3 and 5 
days PI. These large areas of blood, suggestive of leaky vasculature, were replaced over 
time by smaller, vessel-like structures that persisted until 28 days PI. Sirius red/fast green 
staining indicated the persistence of a collagen core within cords for the duration of the 
entire time course (Fig. 2.18B). These collagen-rich areas showed no signs of degradation 
even at 28 days PI, and blood and surrounding cells were largely localized to the 
periphery of cords. To verify the presence of RBCs and endothelial cells of human origin, 
we performed immunohistochemical staining for Ter-119, an erythroid cell marker, and 
human-specific CD31 (Fig. 2.18C). Positive Ter-119 staining confirmed the presence of 
RBCs in all time points, and patterns matched those previously observed with H&E 
staining. Human-specific CD31 staining confirmed that the RBC-containing structures 
were blood vessels comprised of endothelial cells of human origin. These vessels 
appeared large and poorly organized at days 3 and 5 PI, but rapidly organized into 
smaller, lumenized capillaries as early as 7 days PI and persisted until at least 28 days PI. 
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Staining for alpha smooth muscle actin (α-SMA) revealed the presence of α-SMA-
positive cells in a perivascular localization as early as day 3 (Fig. 2.18D). As nascent 
vessels reorganized into smaller capillaries, these α-SMA-positive cells became more 
tightly associated with adjacent endothelial cells indicating that they had adopted a 
pericyte phenotype. 
 
 
Figure 2.18 Implanted EC cords drive formation of mature capillaries. (A) H&E 
staining of tissue constructs containing EC cords resected at days 3, 5, 7, 14 and 28 
PI suggests presence of blood within vessels that organize into small capillaries 
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(arrowheads) by day 7 (bar: 10 µm). (B) Sirius red/fast green staining confirms 
presence of collagen within implanted cords. (bar: 10 µm) (C) Ter-119 (red) and 
human-specific CD31 (green) staining identify RBCs and ECs, respectively. All 
areas containing RBCs also exhibited neighboring human ECs suggesting that 
vessels were patent (bar: 10 µm) (D) α-SMA staining (magenta) and higher 
magnification indicate the presence of α-SMA-positive cells with a perivascular 
localization. These cells appeared more tightly associated with capillaries at days 14 
and 28 PI. (bar: 20 µm) 
 
Quantification of vessels and blood in H&E stained sections further suggested the 
presence of mature capillaries within implanted tissue constructs (Fig. 2.19A). Namely, 
three trends were observed between days 5 and 7 PI: 1) the area of blood within cords 
decreased from approximately 65% to 25% of total cord area; 2) the number of vessels 
within cords increased from approximately 1.5 to 4.0; and 3) the average vessel diameter 
decreased from approximately 30 µm to 7 µm. All trends continued until at least 28 days 
PI and suggest that the cords quickly anastomose (day 3 PI) with the host vasculature to 
form nascent, leaky vessels that form lumens and reorganize into smaller, more numerous 
and mature capillaries (Fig. 2.19B). 
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Figure 2.19 Quantification of the vascularization response (A) Quantification of 
blood area showed a sharp decrease in areas containing blood between 5 and 7 days 
PI. The average number of vessels per cord increased steadily after day 7, while the 
size of the vessels decreased and stabilized at a size of approximately 7.5 um after 
day 5 PI (*: p < 0.05 for comparison of days 7, 14 and 28 vs. 3 and 5 in blood area 
measurements and vessel diameter measurements, days 14 and 28 versus 3, 5 and 7 in 
vessel number measurements, error bars: sem, n ≥ 5). (B) Timeline with qualitative 
description of vascularization trends. 
 
In addition to immunohistochemical techniques, we attempted to better track 
implanted endothelial cells by utilizing fluorescently labeled HUVECs. The labeled cells 
included HUVECs that were stably transduced with H2B:GFP via a lentiviral vector and 
commercially available cells that were also transduced using lentivirus (Angio-
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Proteomie). We found that either population of labeled HUVECs failed to induce 
vascularization in vivo when patterned into cords and implanted. These cells spread to 
cover a larger surface area in culture and proliferated slower than unlabeled cells. Cords 
generated using the labeled HUVECs also appeared ‘frayed’ in appearance and 
contracted to a lesser degree than those generated with control cells. Given these 
abnormalities and lack of a vascularization response, we concluded that these means of 
labeling HUVECs placed too high of a metabolic burden on the cells and prevented them 
from functioning normally in our system. Additionally, successful immunohistochemical 
staining for human-specific CD31 (Fig. 2.18C,D) alleviated the need for labeled cells. 
To gain additional insight into the mechanism of cord-host vessel anastomosis 
and the composition of newly formed capillaries, we injected a cocktail of fluorescently 
labeled human and mouse-specifc lectins via the tail vein (Fig. 2.20). Subsequent 
Fluorescent imaging near the edge of implanted constructs following injection of a 
cocktail containing Helix pomatia agglutinin (HPA)-AlexaFluor488 and Ulex europaeus 
agglutinin I (UEA I)-TRITC indicated that perfused vessels extending beyond the 
boundary of the cords within tissue constructs were of mouse origin (Fig. 2.20A). 
Capillaries within the cords were comprised of a chimera of mouse and human 
endothelial cells. Imaging of host adipose tissue confirmed the lack of cross reactivity 
between UEA I and mouse vessels (Fig. 2.20B). 
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Figure 2.20 Composition of vessels at graft periphery. (A) Staining of constructs 
with mouse-specific (HPA) lectin revealed that vessels extending beyond the 
boundary of the cords were of mouse origin and appeared connected to several 
cord-associated capillaries (dashed line). Staining with human-specific (UEA-1) 
lectin further showed that capillaires within cords exhibited a chimeric 
composition (arrowheads: mouse, arrow: human). (B) Imaging of surrounding 
host adipose tissue confirmed the lack of cross reactivity between UEA I and 
mouse vessels. (bars: 25 µm) 
 
We next attempted to determine whether viable cells were a necessary for cord 
vascularization by implanting tissue constructs consisting of acellular fibrin gels, fibrin 
gels containing HUVECs and 10T1/2s randomly seeded and precultured for 2 days, or 
fibrin gels containing cords that had been ‘decellularized.’ To generate decellularized 
68 
cords, we patterned cells into cords as usual and subsequently induced cell death via snap 
freezing, exposure to hypo- and hypertonic solutions, and dissolution of the cell 
membrane in CHAPS or SDS detergents. Live/dead stains revealed that CHAPS buffer 
followed by 12 hours of PBS washing were most effective at removing cellular 
components without disturbing the surrounding matrix. 
H&E staining of acellular fibrin gels indicated that they remained absent of cells 
and showed no evidence of blood at 7 days PI (Fig. 2.21A). In gels containing 
precultured HUVECs and 10T1/2s, small areas of blood near the periphery of the 
constructs suggested the formation of a small number of capillaries (Fig. 2.21B). Staining 
of ‘decellularized’ cords indicated the presence of small nuclei or DNA fragments near 
areas of collagen matrix, but no blood was evident (Fig. 2.21C). Overall, none of these 
control conditions yielded a vascularization response comparable to that seen upon 
implantation of viable EC cords. 
 
 
Figure 2.21 Cells are required for vascularization (A) H&E staining of acellular 
fibrin gel resected 7 days PI indicates lack of cells and blood. (B) H&E staining of 
fibrin gel containing mixture of HUVECs and 10T1/2s resected 7 days PI. Several 
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areas suggest the presence of RBCs within capillaries. (C) H&E staining of fibrin 
gel containing decellularized EC cords resected 5 days PI. Hematoxylin staining 
suggests the presence of several small nuclei or DNA fragments, but no blood. 
(bars: 25 µm) 
 
 The presence of 10T1/2 cells within cords had no effect on their contraction in 
vitro (Fig. 2.11). Here, we tested whether varying the relative proportions of 10T1/2s and 
HUVECs within implanted cords had an effect on the size of capillaries that form upon 
implantation. At 5 days PI, however, cords containing 2:1, 1:5, or 1:50 ratios of 10T1/2s 
to HUVECs did not seem to impact capillary diameter (Fig. 2.22). Given the known 
contributions of 10T1/2s to the vascularization process (Hirschi et al., 1998; Koike et al., 
2004) and the lack of an observable effect upon their implantation in various ratios, we 
performed the remainder of studies with the originally established 1:50 ratio of 10T1/2s 
to HUVECs. 
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Figure 2.22 Effect of varying 10T1/2 to HUVEC ratios on in vivo capillary 
formation. No observable differences were seen in capillary size upon implantation 
of cords containing 2:1 (A, longitudinal cross-section), 1:5 or 1:50 10T1/2 to 
HUVEC ratios after 5 days in vivo. (bars: 25 µm) 
 
 To determine whether the diameter of the implanted cords could impact the size 
of the resultant capillaries, we implanted tissue constructs containing cords with 50 and 
500 µm diameters (Fig. 2.23). Cells within the smaller cords were distributed randomly 
around the collagen core and contained pools of blood that appeared smaller than 
previously seen (Fig. 2.23A). Upon implantation of larger cords, the pools of blood 
appeared similar in size to those observed upon implantation of 150 µm cords, and the 
cells appeared localized to one side of the collagen core (Fig. 2.23B). Because the pools 
of blood observed in 150 µm cords reorganized into smaller capillaries after 7 days in 
vivo, we concluded that the same phenomenon would be observed in the 500 µm cords 
implanted here. All subsequent EC cord experiments described in this dissertation 
utilized 150 µm cords. 
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Figure 2.23 Effects of cord diameter on vascularization in vivo. H&E staining of 
tissue constructs containing 50 (A) and 500 µm (B) diameter cords resected 5 
days PI. Smaller cords resulted in formation of small pools of blood at the 
periphery of the collagen core. Cells in the larger cords appeared localized to one 
side of the collagen core and indicated the presence of pools of blood similar in 
size to those seen upon implantation of 150 µm cords. (bars: 25 µm) 
 
2.2.3 Implantation of patterned endothelial cell constructs yields a perfused in vivo 
vasculature with conserved geometry 
Networks of implanted endothelial cells and fibroblasts can rapidly anastomose with the 
host circulation (X. Chen et al., 2010). To confirm that capillaries formed upon 
implantation of EC cords had anastomosed with the host vasculature, we performed 
injections of FITC-dextran via the tail vein at day 14 PI. Fluorescent imaging revealed 
the presence of a perfused network of capillaries with an architecture recapitulating that 
of the implanted cords (Fig. 2.24A,B middle panels). Capillaries spanned the entire 
length of the tissue constructs, and sprouts between adjacent capillaries within cords and 
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between capillaries in neighboring cords were also evident. Histological examination of 
tissue constructs resected 7 days PI additionally confirmed the presence of these sprouts 
and capillaries spanning the region between adjacent cords (Fig. 2.25). FITC-dextran 
injections of mice implanted with fibrin gels containing randomly seeded HUVECs and 
10T1/2s did not result in comparable patterning of the vasculature and indicated that 
perfused vessels were present only near the periphery of implanted constructs (Fig. 
2.24A,B middle panels). To investigate whether vascular architecture can be spatially 
patterned, we implanted tissue constructs that contained cords patterned into a Y-shaped 
topology (Fig. 2.24A, right panel). FITC-dextran injection 14 days PI indicated that these 
constructs resulted in the formation of vessels that anastomosed with the host vasculature 
and recapitulated the geometry of the implanted cord pattern (Fig. 2.24B, right panel). 
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Figure 2.24 Perfusion with host blood and patterning of in vivo vasculature. (A) 
Brightfield images of non-implanted tissue constructs containing randomly seeded 
HUVECs and 10T1/2s, parallel EC cords or EC cords patterned into a Y-shaped 
topology (bars: 250 µm, 500 µm, 500 µm) (B) Confocal imaging following FTIC-
dextran injection via the tail vein shows vascular architecture following 
implantation of the tissue constructs shown in A. (bars: 100 µm) 
 
74 
 
Figure 2.25 Capillary sprouting between adjacent cords. 
H&E staining of EC cords in longitudinal cross-section 
reveals presence of capillaries between adjacent cords 
(arrow). Arrowheads indicate locations of cords. (bar: 25 µm) 
 
2.2.4 Patterned vasculature within engineered hepatic tissues maintains hepatocyte 
function 
Improved vascular organization enhances the integration of engineered and host tissues 
(Koffler et al., 2011). To test the ability of patterned EC cords to vascularize engineered 
tissues and improve their function in vivo, we generated tissue constructs that contained 
patterned EC cords and aggregates of primary rat liver hepatocytes (Fig. 2.26A). A 
lentiviral vector was used to transduce the hepatocytes to express luciferase under control 
of the albumin promoter. Bioluminescence imaging over 20 days following implantation 
revealed that hepatocyte constructs containing cords exhibited significantly higher levels 
of albumin promoter activity for at least 20 days (Fig 2.26C). Histological examination 
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revealed clusters of aggregates adjacent to vessels containing blood and deposits of 
collagen mimicking those previously found in the cords (Fig. 2.26B). Sirius red/fast 
green staining suggested that collagen previously present in the EC cords had been 
largely degraded and dense areas of elastin-rich matrix had been deposited by the 
hepatocyte aggregates. Immunofluorescent staining for Ter-119 and arginase 1, a 
hepatocyte marker, confirmed the presence of blood in areas directly adjacent to 
hepatocyte aggregates. These staining patterns suggested that the implanted hepatocytes 
remained viable for at least 20 days in vivo and had access to the host blood supply via 
capillaries that formed as a result of the implanted cords. 
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Figure 2.26 EC cords within engineered rat hepatic tissues improve function (A) 
Three types of tissue constructs containing varying combinations of primary 
hepatocyte aggregates and ECs were generated: 1) hepatocyte aggregates only, 2) 
hepatocyte aggregates with randomly seeded HUVECs and 10T1/2s, and 3) 
hepatocyte aggregates with EC cords (bar: 20 µm). (B) H&E and sirius red/fast 
green staining revealed hepatocyte aggregates in close proximity to vessel-like 
structures that contained blood. Immunostaining for Ter-119 (green) and arginase 
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1 (red) confirmed the presence of RBCs in close proximity to viable hepatocyte 
aggregates at 20 days PI. (bars: 25 µm) (C) Luciferase activity showed 
significantly increased albumin promoter activity in the group of tissue constructs 
containing patterned rat hepatocyte aggregates and EC cords at least 20 days PI (n 
≥ 5, error bars: sem). 
 
 Next, we used primary human hepatocytes to investigate the effects of co-
implanting patterned hepatocyte aggregates and EC cords. Histological analysis again 
showed that hepatocyte aggregates co-implanted with EC cords had access to host blood 
via adjacent capillaries (Fig. 2.27A). Luciferase imaging throughout the experiment 
indicated that hepatocyte aggregates co-implanted with EC cords exhibited significantly 
higher levels of albumin promoter activity (Fig. 2.27B). In an additional control 
condition, we ligated the host vessels within the parametrial fat pad immediately 
following implantation of the tissue constructs. Low albumin promoter activity within 
this group further suggested that the observed increases in hepatocyte function were a 
result of improved access to the vasculature rather than paracrine signaling alone. 
Measurements of serum albumin at day 18 PI supported the trends observed via 
luciferase imaging. Due to the low levels of serum albumin in all groups, however, these 
results were not statistically significant. 
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Figure 2.27 EC cords within engineered human hepatic tissues improve function. 
(A) H&E and sirius red/fast green staining suggested that hepatocyte aggregates 
were in close proximity to vessels that contained blood. Immunostaining for Ter-
119 (green) and arginase 1 (red) confirmed the presence of RBCs in close 
proximity to viable hepatocyte aggregates at 18 days PI. (bars: 25 µm) (B) 
Luciferase imaging revealed that constructs in the ‘no EC,’ ‘random EC,’ and 
‘ligated’ control groups expressed similar levels of albumin expression. 
Constructs containing aggregates patterned with EC cords performed significantly 
better than control groups for at least 18 days PI (n ≥ 6, error bars: sem). ELISA 
measurements suggested that serum albumin levels in all groups were comparable 
to those measured via luciferase imaging. 
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2.4 Materials and Methods 
Cell culture 
Primary human umbilical endothelial cells (HUVECs, Lonza) were cultured on 0.1% 
gelatin-coated dishes in EGM-2 (Lonza).  C3H10T1/2 cells [American Type Culture 
Collection (ATCC)] were cultured in low glucose DMEM containing 10% fetal bovine 
serum (Atlanta Biologicals), 100 units/mL penicillin, and 100mg/mL streptomycin 
(Invitrogen). Primary human hepatocytes were cryopreserved and from a 1-yr-old female 
Caucasian donor (Lot Hu8085; CellzDirect).  Human hepatocytes were cultured in high 
glucose DMEM (Cellgro) containing 10% fetal bovine serum (FBS; Gibco), 1% (vol/vol) 
ITS supplement (insulin, human transferring, and selenous acid; BD Biosciences), 0.49 
pg/ml glucagon, 0.08 ng/ml dexamethasone, 0.018 M HEPES, and 1% (vol/vol) 
penicillin-streptomycin (pen-strep; Invitrogen). J2-3T3 fibroblasts (gift of Dr. Howard 
Green; Harvard Medical School) were cultured in high glucose DMEM containing 10% 
bovine serum, and 1% penicillin-streptomycin. 
Primary rat hepatocytes (2 – 3 month old adult female Lewis rats; Charles River) 
were isolated as described previously (A. A. Chen et al., 2011; Dunn, Tompkins, & 
Yarmush, 1991; Seglen, 1976).  Each rat was anesthetized and the portal vein was 
cannulated. The liver was perfused with buffers followed by collagenase. Liver digest 
was purified using Percoll centrifugation, and hepatocyte viability was typically 85 – 
95% using trypan blue exclusion. Rat hepatocytes were cultured in high glucose DMEM 
containing 10% (v/v) FBS, 0.5 U/ml insulin (Lilly), 7 ng/ml glucagon (Bedford 
Laboratories), 7.5 µg/ml hydrocortisone (Sigma), and 1% pen-strep.  
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Fabrication of PDMS templates and preparation of endothelial cell cords 
Endothelial cell cords were micropatterned as previously described.  Briefly, masters 
were prepared by photolithographically exposing silicon wafers coated with SU-8 
photoresist (Shipley) to develop channel patterns at a height of 150um.  Liquid poly 
(dimethylsiloxane) (PDMS) pre-polymer was poured onto the silicon masters and cured 
to generate molded substrates. The PDMS substrates were sterilized with UV, and treated 
with 0.01% Pluronic F127 for 10 minutes prior to use as culture substrates. HUVECs and 
10T1/2s were suspended at a ratio of 50:1 in 2.5mg/mL liquid collagen (BD Biosciences) 
and centrifuged into the PDMS channels.  Excess unpolymerized collagen and cells were 
removed by dewetting the surface of the substrate.  The collagen was polymerized, 
growth medium was added, and the constructs were incubated for 4-6 hours.  The newly 
formed cords were removed from the PDMS substrates by inverting onto a drop of 
unpolymerized 7.5 mg/mL bovine fibrin (sigma).  After the fibrin was polymerized at 37  
oC, the constructs were submerged in PBS and the culture dish was gently agitated to 
dislodge the PDMS.  The PBS was aspirated and a second layer of unpolymerized fibrin 
was added over the top and polymerized to fully encase the cords. The embedded cords 
were cut with a 6 mm biopsy punch prior to implantation. 
 
Decellularization of cord constructs 
Cord constructs were prepared as described above and subsequently decellularized using 
a solution containing 8 mM CHAPS, 1 M NaCl, 25 mM EDTA in PBS. During the 
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decellularization process, constructs were submerged in the decellularization solution and 
placed on an orbital shaker overnight. Excess cellular debris and detergent were then 
removed by soaking the constructs in PBS on an orbital shaker for several hours. Wash 
steps were repeated three times. The decellularized constructs were then cut with a 6 mm 
biopsy punch as described above. 
 
Construction of hepatic engineered tissues 
To enable noninvasive imaging of hepatocyte function and survival in engineered tissues, 
hepatocytes were transduced in suspension culture immediately after isolation (for rat 
hepatocytes) or thaw (for human hepatocytes) with a lentiviral vector expressing firefly 
luciferase under the human albumin promoter ((pTRIP.Alb.IVSb.IRES.tagRFP-DEST, 
gift of Charles Rice, The Rockefeller University). Hepatocytes and J2 fibroblasts were 
placed into Aggrewell micromolds overnight to form hepatic aggregates (average of 100 
hepatocytes and 25 J2 fibroblasts per aggregate). Hepatic aggregates were removed from 
Aggrewell templates and suspended randomly in 7.5mg/mL unpolymerized bovine fibrin 
at a concentration of 15K/mL for the random aggregates condition.  For the random 
aggregates plus random HUVEC condition, hepatic aggregates were suspended randomly 
in 7.5 mg/mL unpolymerized bovine fibrin at a concentration of 15k/mL along with 2 
million HUVECs/mL and 10T1/2s at a 50:1 ratio.  For the aggregates plus cords 
condition, cords were embedded in 7.5mg/mL bovine fibrin containing randomly 
suspended hepatic aggregates at a concentration of 15K/mL. 
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In vitro imaging of endothelial cell cords 
HUVECs were labeled with 5 ug/mL Calcein AM red-orange and 10T1/2s were labeled 
with 5ug/mL Calcein AM (invitrogen) prior to trypsinization.  PDMS substrates were 
prepared and seeded as above.  Cord contraction was imaged using an Eclipse 
epifluorescent microscope.  Final cord morphology was imaged using a Zeiss 710 laser 
scanning confocal microscope. For measurements of cord contraction, cords were treated 
with 20 µM blebbistatin or 25 µM Y27632 at 7.5 or 6.5 hours after seeding, respectively. 
For in vitro imaging of hepatic constructs, Huh7.5 cells were labeled with 5 
ug/mL calcein AM and placed into Aggrewell micromolds overnight to form aggregates 
(approximately 100 cells per aggregate). Aggregates were removed from Aggrewell 
templates and suspended in 7.5mg/mL unpolymerized bovine fibrin at a concentration of 
15K/mL for the ‘No EC’ condition. For the ‘random EC’ condition, aggregates were 
suspended in 7.5 mg/mL unpolymerized bovine fibrin at a concentration of 15k/mL along 
with 2 million HUVECs/mL and 10T1/2s at a 50:1 ratio. HUVECs and 10T1/2s were 
labeled with 5 ug/mL calcein red orange. For the ‘EC cords’ condition, cords were 
embedded in 7.5mg/mL bovine fibrin containing randomly suspended hepatic aggregates 
at a concentration of 15K/mL.  Constructs were imaged using a Zeiss Axiovert 200m 
microscope equipped with a Yokogawa spinning disk confocal unit. 
 
In vivo implantation of cords 
For cord only experiments, all surgical procedures were conducted according to protocols 
approved by the University of Pennsylvania Institutional Animal Care and Use 
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Committee.  Eight week old female Nu/Nu athymic mice (Charles River) were 
anesthetized using isoflurane and the constructs were sutured to the parametrial fat pad. 
The incisions were closed aseptically, and animals were administered 0.1 mg/ml 
buprenorphine every 12 hours for three days following surgery. 
For hepatic engineered constructs, all animal procedures were approved by The 
Committee for Animal Care in the Department of Comparative Medicine at 
Massachusetts Institute of Technology. Immediately after engineered tissue fabrication, 
NCr nude mice (Taconic) were anesthetized using isoflurane, and engineered tissues were 
sutured to the mesenteric parametrial fat pad. For ‘cords + hepatocytes – excised’ 
animals, engineered tissue and attached mesentery were cut from the remainder of the 
mesentery via an upstream excision such that the tissue and attached mesentery were no 
longer directly connected to host circulation. The incisions were closed aseptically, and 
animals were administered 0.1 mg/ml buprenorphine every 12 hours for three days 
following surgery. 
 
Bioluminescence imaging 
For luminescence imaging, mice were injected intraperitoneally with 250 µL of 15 
mg/mL D-Luciferin (Caliper Life Sciences) and then imaged using the IVIS Spectrum 
(Xenogen) system and Living Image software (Caliper Life Sciences).  
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Dextran perfusion, lectin perfusion and imaging 
To preserve geometry during implantation, cords were embedded in a gasket cut from a 
polypropylene surgical mesh (Davol). To visualize perfused vessels a 200uL solution of 
20mg/mL fluorescein isothiocyanate (FITC)-labeled dextran (150 kDa) (Sigma) in PBS 
was injected intravenously via the tail vein.  To visualize mouse versus human vessels, a 
200uL solution of 500µg/ml lectin from Helix pomatia agglutinin (HPA) conjugated to 
Alexa 488 (Sigma), and 100µg/ml lectin from Ulex europaeus agglutinin (UEA-1) 
conjugated to TRITC (Vector labs) in PBS was injected intravenously via the tail vein.  
Animals were sacrificed and tissue was harvested from graft site immediately after 
injection. Perfused vessels were subsequently imaged using a Zeiss 710 laser scanning 
confocal microscope. 
 
Tissue harvesting, processing and histology, and immunohistochemistry 
Animals were sacrificed at various time points and tissue was harvested from the 
intraperitoneal space.  Explants were fixed in 4% PFA for 48 hrs at 4˚C , dehydrated in 
graded ethanol (50-100%), embedded in paraffin, and sectioned using a microtome (6um) 
for immunohistochemical staining.  For gross visualization of tissue, sections were 
stained with hematoxylin and eosin (H&E).  For identification of cords composed 
partially of collagen, sections were stained with Sirius red (collagen) and fast green (other 
tissue elements). 
For identification of vessels containing human endothelial cells, smooth muscle 
cells, and erythroid cells, sections were first blocked using M.O.M. blocking reagent 
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(Vector Labs) and normal goat serum and then immunostained using primary antibodies 
against human CD31 (1:20; DAKO), Ter-119 (1:100; BD Biosciences), and smooth 
muscle alpha-actin (1:100, Abcam). Signal was visualized after incubation with 
secondary goat anti-IgG1-Alexa 555, goat anti-rat-Alexa 488, and donkey anti-rabbit-
Alexa 647 antibodies (Jackson ImmunoResearch). For identification of primary 
hepatocytes adjacent to vessels containing red blood cells, sections were blocked using 
normal donkey serum then incubated with primary antibodies against arginase-1 (ARG1, 
1:400, Sigma) and Ter-119 and followed with species-appropriate secondary antibodies 
conjugated to Alexa 488 and 555. Images were obtained using a Zeiss 710 laser scanning 
confocal or Nikon 1AR Ultra-Fast Spectral Scanning Confocal Microscope.    
 
Biochemical assays to assess hepatocyte function 
Rat albumin in sampled media was quantified by enzyme-linked immunosorbent assay 
(ELISA) using a rat albumin ELISA kit (Bethyl labs; sheep anti-rat albumin antibody at 
1:100).  
 
Statistical Analysis and Quantification of Vascularization Parameters 
Quantification was performed on H&E sections of fully engrafted cord constructs. Blood 
area was quantified by measuring the total area of tissue containing blood within a cord. 
This measurements was normalized to average cord area to compensate for oblique 
cutting angles. Vessel number was quantified by counting individual vessels within a 
cord and was normalized to the average cord area.  Vessel diameter was quantified by 
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measuring the diameter of individual vessels within a cord. Sections for quantification 
were chosen from the center of the constructs, and a minimum of 3 sections at least 
150uM apart were quantified per cord. All data are expressed as the mean ± standard 
error. Statistical significance was determined using the one-way ANOVA followed by 
Tukey’s post hoc test for group comparisons. 
 
2.5 Conclusions 
In the work described here, we have developed a novel technique for generating 
functional capillaries with spatially controlled geometry in vivo. Via adapting a 
previously described system for patterning cells into organized cords, we have created a 
strategy for embedding cords into implantable tissue constructs. The implantation of 
these constructs into mice led to the formation of functional capillaries that become 
perfused with blood within 3 days PI and remain stable and exhibit a mature phenotype 
for up to 28 days PI. The capillary networks are perfused with host blood, contain vessels 
that are largely comprised of implanted human cells, and exhibit a geometry that 
recapitulates that of the implanted EC cords. Previous studies have suggested that the 
ability to pattern vessels is essential for the function and proper engraftment of 
engineered tissues ((X. Chen et al., 2009; Koffler et al., 2011)). Here, we have further 
validated these findings by demonstrating that patterned EC cords used to vascularize 
engineered hepatic tissues were capable of significantly improving function. 
Future studies in vascular tissue engineering will require the development of 
defined complex vessel architectures. Our data provide one of the first demonstrations of 
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capillary network patterning in vivo and further suggest that this approach is a viable 
strategy for vascularizing engineered solid tissues. We envision that the vascular 
patterning technique described her will enable future studies toward the design of optimal 
vessel architectures within a variety of tissue engineered contexts. 
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CHAPTER 3: Proliferative regulation by adhesion and RhoGTPases in 
smooth muscle cells is altered in idiopathic pulmonary arterial 
hypertension 
 
3.1 Introduction 
Organotypic models provide a powerful tool for studying disease processes in vitro while 
maintaining an added level of physiologic relevance that is not present in traditional 
tissue culture models. While angiogenic models that rely on tubes or channels coated 
with endothelial cells are common, more complex models of the arterial smooth muscle 
compartment have been seldom used in mechanistic studies (Chrobak et al., 2006; 
Zervantonakis et al., 2012). Niwa et al. and Fillinger et al. have previously described 
techniques for generating bilayers of endothelial and smooth muscle cells (Fillinger et al., 
1997; Niwa et al., 2007). Here, we sought to generate an EC-SMC bilayer and utilize it in 
the study of cells isolated from patients with pulmonary hypertension. Given a lack of 
promising results, however, we continued with an investigation into the pathobiology of 
pulmonary hypertension using traditional tissue culture models. 
Pulmonary arterial hypertension (PAH) is a disease characterized by 
hyperproliferation and remodeling within the small pulmonary arteries, which results in 
increased blood pressure within the lung vasculature (Gaine & Rubin, 1998; Ikeda et al., 
2010; Rubin, 1997). In patients with PAH, the increased vascular resistance in the 
pulmonary circulation places a greater workload on the heart and ultimately leads to right 
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ventricular failure and premature death. Idiopathic pulmonary arterial hypertension 
(IPAH), which occurs in the absence of identifiable risks, is particularly difficult to 
diagnose (Chin & Rubin, 2008; Thyberg et al., 1990). Patients present with general 
symptoms and diagnosis is only made after the exclusion of other heart and lung diseases 
known to cause elevations in pulmonary arterial pressure. In patients with IPAH, the 
estimated survival rates for patients receiving treatment at 1, 2, and 3 years are 83, 67, 
and 58%, respectively (Aoyagi et al., 1997; Humbert et al., 2010; Jones & Rabinovitch, 
1996; Monahan et al., 2007; Stouffer et al., 1998). Despite advances in the management 
of IPAH and increases in survival rates, patients’ quality of life remains low and no 
further treatments outside of the realm of lung transplantation currently exist. 
Histological examination of pulmonary arterioles in patients with IPAH shows 
neointimal thickening, pulmonary arteriolar occlusion, and plexiform lesions, suggesting 
that IPAH is a primarily vasoproliferative disease with accompanying vasoconstriction as 
well as catabolism and de novo synthesis of components of the extracellular matrix 
(ECM) (Burridge & Chrzanowska-Wodnicka, 1996; Chin & Rubin, 2008; Farber & 
Loscalzo, 2004; Guan & Shalloway, 1992; Humbert et al., 2004; Jones et al., 1997; Jones 
& Rabinovitch, 1996; Kornberg, Earp, Parsons, Schaller, & Juliano, 1992; Pietra et al., 
1989). Studies into the mechanisms underlying abnormal PASMC proliferation in IPAH 
have only recently begun, however, and this area of research still remains largely 
unexplored (Chrzanowska-Wodnicka & Burridge, 1996; Ikeda et al., 2010; Lewis & 
Schwartz, 1995; Richardson, Malik, Hildebrand, & Parsons, 1997; Roovers & Assoian, 
2003). 
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In vivo, the proliferation of SMCs is tightly regulated by many extracellular cues 
including cell adhesion to the extracellular matrix (ECM), the presence of soluble growth 
factors and cell-cell adhesion. In adult tissues, SMC proliferation is generally low and the 
cells exhibit a differentiated phenotype that enables proper maintenance of vascular tone 
and regulation of blood pressure.  Upon injury and in the presence of the proper 
extracellular cues, however, SMCs can undergo a switch to a more synthetic, highly 
proliferative phenotype (Pirone et al., 2006; Thyberg et al., 1990).  In this state, the 
SMCs become highly proliferative and exhibit increased migration and ECM production. 
Specifically, the production of ECM proteins including collagen, fibronectin, elastin, 
tenascin-C, and proteoglycans increases, and the expression of adhesion molecules such 
as integrins and cadherins is altered (Aoyagi et al., 1997; Danen, Sonneveld, Sonnenberg, 
& Yamada, 2000; Jones & Rabinovitch, 1996; Monahan et al., 2007; Ren & Schwartz, 
2000; Stouffer et al., 1998; Welsh et al., 2001).  Given the presence of a pathologic 
cellular microenvironment in the arteries of IPAH lungs, we sought to investigate 
whether adhesive signaling might be altered in PASMCs isolated from IPAH patients and 
whether this might impact proliferation of IPAH patient-derived PASMCs. 
Adhesion-mediated proliferation in SMCs is facilitated by the binding and clustering of 
integrins to ECM proteins, ultimately forming focal adhesions.  Mature focal adhesions 
serve dual roles as signaling hubs and as mechanical linkages between a cell and its 
extracellular environment.  Focal adhesion kinase (FAK) is a key effector in focal 
adhesion signaling whose kinase activity is activated upon integrin ligation (Burridge & 
Chrzanowska-Wodnicka, 1996; Guan & Shalloway, 1992; Kornberg et al., 1992; Pirone 
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et al., 2006). FAK is involved in the development of focal adhesions allowing for cell 
spreading and the establishment of cytoskeletal tension (C. Chen, Mrksich, Huang, 
Whitesides, & Ingber, 1997; Chrzanowska-Wodnicka & Burridge, 1996; Lewis & 
Schwartz, 1995; Richardson et al., 1997; Roovers & Assoian, 2003).  Notably, FAK has 
also been implicated as a key player in adhesion-mediated proliferative control via the 
RhoA signaling pathway, which is downstream of cell adhesion to the extracellular 
matrix (Chrzanowska-Wodnicka & Burridge, 1996; Pirone et al., 2006). Specifically, 
FAK regulates the activity of the Rho GTPase RhoA, which is required for sustained 
ERK signaling and cell cycle progression (C. Chen et al., 1997; Danen et al., 2000; 
Raines, 2000; Ren & Schwartz, 2000; Welsh et al., 2001). 
Herein, we investigated the proliferative control mechanisms at work in PASMCs 
isolated from patients with advanced IPAH. We found that IPAH PASMCs showed 
significantly increased proliferation in vitro as compared to normal controls. While 
control cells exhibit a Rac-regulated proliferative control mechanism, IPAH cells appear 
to be Rho- dependent. Additionally, IPAH PASMCs exhibit several abnormalities in 
adhesion signaling including increased focal adhesion size, higher FAK phosphorylation 
levels, and loss of spreading-dependent proliferative control. Inhibition of FAK restored 
normal adhesion- mediated proliferation control suggesting that altered adhesion 
signaling might underlie the abnormal proliferation of PASMCs in IPAH. 
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3.2 Development of an organotypic arterial wall model 
To generate an in vitro model of an arterial wall, we sought to create a bilayer structure 
consisting of endothelial cells (intima) grown atop a layer of smooth muscle cells and 
ECM (media). Treatment of SMCs with ascorbic acid leads to increased collagen 
production, decreased proliferation, and increased expression of smooth muscle markers 
(Arakawa et al., 2003; Niwa et al., 2007; Qiao, Bell, Juliao, Li, & May, 2009). By 
stimulating bovine pulmonary arterial smooth muscle cells (bPASMCs) with ascorbic 
acid, we first attempted to create an ECM rich layer of smooth muscle cells. 
Immunofluorescent staining suggested that treatment with 50 µg/ml ascorbic acid of 
bPASMCs cultured on fibronectin-coated glass increased expression of α-smooth muscle 
actin and decreased proliferation (Fig. 3.1A). Further culture of these cells in the presence 
of ascorbic acid, however, did not seem to affect their morphology or the rate at which 
they reached confluence (Fig. 3.1B). Additionally, confluent cells appeared growth 
arrested and did not continue proliferating to form a multilayered structure as expected. 
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Figure 3.1 Ascorbic acid treatment of bPASMCs (A) Immunostaining indicated 
that bPASMCs cultures treated with ascorbic acid exhibited increased α-SMA 
expression (red) within 24 hours of seeding. Decreased numbers of nuclei (blue) 
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also suggested that ascorbic acid treatment decreased proliferation. (bars: 20 µm) 
(B) Time lapse phase contrast imaging over 8 days did not show any observable 
differences in cultures of bPASMCs treated with ascorbic acid and control cells. 
(bars: 50 µm) 
 
We next attempted to seed a monolayer of endothelial cells atop confluent layers 
of smooth muscle cells. We seeded bovine pulmonary arterial endothelial cells (BPAECs) 
at a density of 100,000 cells/cm2 atop confluent layers of bPASMCs treated with ascorbic 
acid (Fig. 3.2A, B). The bPAECs were labeled with CMTPX CellTracker dye and imaged 
for 10 hours. While the bPAECs appeared to attach and remain viable, they did not 
spread and proliferate to form a monolayer. Extended times in culture confirmed that the 
bPAECs did not proliferate and appeared to invade the layer of bPASMCs underneath 
and adhere to the glass substrate below. Seeding bPAECs at a higher density (200,000 
cells/cm2) yielded similar results (Fig. 3.3A, B). The higher density of endothelial cells 
present at the start of the experiment allowed for direct contact between neighboring 
cells. While we had hypothesized that this presence of cell-cell contacts might stimulate 
the bPAECs to remain as a monolayer, similar results to those utilizing the lower 
concentration of bPAECs were observed. 
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Figure 3.2 bPAECs (100,000 cells/cm2) grown atop a layer of bPASMCs. 
Combined fluorescence and phase contrast imaging of 100,000 bBPAECs (red) 
seeded onto a confluent layer of bPASMCs (unlabeled) that were either 
untreated (A) or treated with 50 µg/ml ascorbic acid (B). bPAECs attached, but 
remained rounded and failed to proliferate and form a monolayer. (bars: 100 
µm) 
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Figure 3.3 bPAECs (200,000 cells/cm2) grown atop a layer of bPASMCs. 
Combined fluorescence and phase contrast imaging of 100,000 bBPAECs (red) 
seeded onto a confluent layer of bPASMCs (unlabeled) that were either 
untreated (A) or treated with 50 µg/ml ascorbic acid (B). bPAECs attached, but 
remained rounded and failed to proliferate and form a monolayer. (bars: 100 
µm) 
 
 Given the failure of bPAECs to spread atop layers of bPASMCs, we sought to 
generate a ‘reversed’ aortic wall model by culturing smooth muscle cells atop endothelial 
cells. While such a model would be slightly less physiologically relevant, we 
hypothesized that it might still be useful for testing a variety of physiologically relevant 
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phenomena in an in vitro setting. To create this ‘reversed’ arterial model, we seeded 
bPASMCs onto a monolayer of bPAECs. Imaging of bPASMCs transduced with GFP via 
an adenoviral vector cultured atop bPAECs treated with DiI-AcLDL, however, indicated 
that the bPASMCs did not remain on the top surface of the endothelial monolayer (Fig. 
3.4). Rather, the ECs and SMCs seemed to mix randomly and failed to create a 
multilayered structure that might mimic arterial physiology. 
 
 
Figure 3.4 ‘Reverse’ arterial wall model. 15um z-stack of bPASMCs 
cultured atop a monolayer of bPAECs. bPASMCs were transduced with 
GFP (green) via an adenoviral vector, bPAECs labeled with DiI-AcLDL. 
X-Z (top) and Y-Z (right) projections indicate that SMCs did not remain 
positioned on top of the EC monolayer. (bar: 10 µm) 
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3.3 Contractility measurements of IPAH PASMCs 
Given the challenges in readily generating an arterial wall model, we performed a number 
of characterizations of PASMCs isolated from the lungs of patients with IPAH using 
more traditional tissue culture models. First, to determine whether these cells might be 
contributing to the hypertensive state via increased contractility, we examined the levels 
of myosin light chain (MLC) phosphorylation (Fig. 3.5). Comparison of donor cells from 
one IPAH lung versus control cells revealed only a minor increase in ppMLC expression. 
Treatment with several cytoskeletal tension inhibitors (Y27632: RhoA, ML-9: myosin 
light chain kinase, blebbistatin: myosin II, NSC 23766: Rac1) led to a differential 
response between the two cell populations when treated with ML-9. Treatment with 
blebbistatin, however, did not lead to decreased ppMLC expression in either cell 
population. 
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Figure 3.5 ppMLC expression levels in IPAH PASMCs. (A) Quantification of 
western blot for ppMLC in lysates from IPAH and control PASMCs. Lanes in B 
are 1) DMSO, 2) Y27632, 3) ML-9, 4) blebbistatin, 5) NSC 23766, 6) Y27632 + 
NSC 23766 in control cells, and 7) DMSO, 8) Y27632, 9) ML-9, 10) blebbistatin, 
11) NSC 23766, 12) Y27632 + NSC 23766 in IPAH PASMCs isolated from lung 
#8. 
 
The lack of a decrease in phosphorylation levels of MLC upon treatment with 
blebbistatin led us to pursue assays with direct functional read outs of contractility. We 
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employed a collagen gel contractility assay to compare the ability of IPAH and control 
SMCs to contract a free floating collagen gel (Fig. 3.5). IPAH PASMCs cultured for 4 
days in 2.5 mg/ml collagen gels showed no clear trends in differences in contractility 
versus control PASMCs. Only cells isolated form IPAH Lung 1 exhibited decreased 
contractility. Cells from other donors exhibited contractility levels very similar to those 
observed in control PASMCs. 
 
 
Figure 3.6 IPAH SMC contractility in collagen gels. Percent contraction of 
collagen gels containing IPAH and control PASMCs cultured for 4 days.  
 
 To better understand the contractile behavior of IPAH and control cells, we 
employed microfabricated post-array detectors (mPADs) to directly measure the traction 
forces exerted by individual cells (Fig. 3.7A) (Tan et al., 2003). Deflections measured 
upon seeding control and IPAH PASMCs onto mPADs showed only a moderate increase 
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in the IPAH cells (Fig. 3.7B). mPAD devices allowed us to make a variety of 
measurements including force per post, force per cell, and cell area. Measurements of cell 
area indicated that the IPAH SMCs spread to slightly larger areas. This increase in spread 
area contributed slightly to the total force per cell exerted by these cells. When cells with 
similar areas were compared, no differences in total traction force were observed. The 
most significant difference in traction forces were observed in measurements of traction 
force per post.  These differences, however, were not statistically significant when 
compared via a student’s t-test (p > 0.05). 
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Figure 3.7 Measurements of traction forces generated by IPAH PASMCs. (A) 
Representative images of control and IPAH PASMCs seeded onto mPADs. (red: 
DiI, tops of PDMS posts, arrows: force vectors) (bar: 10 µm) (B) Measurements 
of force exerted per post by control and IPAH PASMCs. (errors bars represent sd 
in expts. 1, 2, and 3 and sem in pooled data, measurements of at least 20 cells of 
each type were made in each experiment). 
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3.4 Further characterization of IPAH PASMCs 
Observations of the IPAH PASMCs in routine culture suggested that they may exhibit an 
altered adhesive behavior. To test this hypothesis, we labeled control and IPAH SMCs 
with CyQUANT dye and determined the relative numbers of cells that remained attached 
to substrates coated with varying concentrations of fibronectin after 45 minutes. We 
performed this adhesion assay with 3 control and 3 IPAH cell lines, which were newly 
acquired. Results indicated that cells from all 6 cell lines were able to adhere in much 
larger quantities when the fibronectin concentration was increased to at least 1 µg/ml Fig. 
3.8). Differences between individual or pooled control and IPAH groups were not 
significant. Minor variations to this tend were observed at individual time points but no 
significant trends were observed overall. 
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Figure 3.8 Adhesion of control and IPAH PASMCs to fibronectin-coated 
substrates. Quantification of control and IPAH cells labeled with CyQUANT and 
seeded onto polystyrene substrates coated with varying concentrations of 
fibronectin (measurements represent average of three replicate wells per 
condition). 
 
 Given that aberrant proliferation of vascular cells is a hallmark of pulmonary 
hypertension, we decided to investigate the proliferative behavior of IPAH SMCs (Chin 
& Rubin, 2008). First, we confirmed that both control and IPAH PASMCs grown to 
confluence and treated with serum free medium ceased proliferating and remained viable 
in culture. Once a successful synchronization protocol was established, we investigated 
the effects of seeding density on proliferation in both control and IPAH cells. IPAH and 
control cells both exhibited a biphasic response in proliferation rates when seeded at low, 
medium or high densities (Fig. 3.9A). Proliferation reached a maximum at medium 
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density (some cell-cell contact but not yet confluent) and a minimum at low (little to no 
cell-cell contacts) and high (near confluence) densities. In general, IPAH PASMCs were 
found to proliferate at rates approximately twice as high as those in control cells. To 
further investigate whether cell-cell contacts may be abnormal in IPAH cells, we assayed 
the basal expression levels of N-cadherin. Western blots indicated that N-cadherin 
expression in IPAH cells was significantly lower than in control cells. Additionally, we 
found that IPAH and control PASMCs transduced via an adenoviral vector with a 
dominant negative form of N-cadherin proliferated at similar rates. This result suggested 
that proliferation in IPAH SMCs could be lowered to normal levels by knockdown of N-
cadherin. More extensive studies of proliferative regulation in IPAH PASMCs are 
described in section 3.5 below. 
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Figure 3.9 Effects of cell density and N-cadherin expression on IPAH PASMC 
proliferation (A) Both control and IPAH PASMCs exhibit a biphasic response in 
proliferation to varying levels of cell density. Overall proliferation rates were 
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approximately two-fold higher in IPAH cells (data represent at least 150 cells of 
each type counted from a single experiment). (B) IPAH PASMCs expression 
levels are approximately one-fourth lower than in control cells (data represents 
one experiment) (C) Expression of dominant negative N cadherin significantly 
lowered proliferation rates in both IPAH and control cells. Proliferation in IPAH 
PASMCs expressing NΔ dropped to levels below those in control cells (data 
represent average proliferation rates of at least 150 cells in each condition from a 
single experiment). 
 
To further characterize the phenotype of IPAH PASMCs, we performed 
quantitative real-time PCR analysis for a panel of SMC differentiation markers. We 
found that all SMC differentiation markers examined (smooth muscle actin α-2, calponin, 
myocardin, SM22α and smoothelin) were downregulated in the IPAH PASMCs (Figure 
3.10). Taken together, the proliferation and gene expression data suggest that the IPAH 
PASMCs are likely to have undergone a switch from a differentiated to a less 
differentiated, highly proliferative phenotype. Subsequent analysis of additional IPAH 
donor cells, however, indicated that the observed trends were evident in only one IPAH 
PASMC cell line. 
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Figure 3.10 SMC marker expression levels of control versus IPAH PASMCs. 
SMC marker expression levels were measured by qRT-PCR. Cells were G0 
synchronized, replated at a density of 5,000 cells/cm2 prior to RNA isolation. 
(data are expressed as ± SEM from at least 3 independent experiments. *, p < 
0.05) 
 
 Previous studies have shown that decreased expression levels of the basement 
membrane protein perlecan might contribute to SMC hyperplasia in vivo (Tran et al., 
2004). Immunofluorescent staining of IPAH PASMCs suggested that they might express 
reduced levels of perlecan in culture (Fig. 3.11). While it is plausible that IPAH PASMCs 
exhibit abnormal expression levels of ECM proteins in culture, these findings remain to 
be confirmed by western blot analysis and in a variety of donor cell lines. 
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Figure 3.11 Perlecan deposition patterns in IPAH PASMC cultures. Cells were 
plated at a density of 5,000 cells/cm2 and fixed 24 hours later. Staining patterns 
suggest that perlecan deposition by IPAH PASMCs may be lower than those in 
control cells. (bars: 25 µm) 
 
 
3.5 Proliferative regulation by adhesion and Rho GTPases is altered in 
IPAH PASMCs 
3.5.1 Proliferation in IPAH SMCs is Rho-dependent 
To test whether SMCs isolated from lungs of patients with IPAH exhibited a 
hyperproliferative phenotype in vitro, we cultured isolated PASMCs and measured their 
rate of S phase entry via a bromodeoxyuridine incorporation assay. PASMCs isolated 
from diseased lungs of multiple donors showed a significant increase in proliferation over 
control cells isolated from individuals without PAH (Fig. 3.12A).  These results suggest 
that SMCs from patients IPAH retain their in vivo hyperproliferative phenotype when 
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isolated. Additionally, routine observation of control and IPAH SMCs in culture 
indicated the possibility of differences in adhesion between the IPAH and control cells.  
Specifically, the IPAH SMCs appeared to attach and spread more quickly than control 
cells (data not shown).  Because the small GTPases RhoA and Rac 1 play known roles in 
cytoskeletal reorganization during cell spreading and in proliferative control, we 
investigated whether the RhoA or Rac 1 signaling pathways were involved in the 
proliferative control of IPAH PASMCs.  After synchronizing control and IPAH PASMCs 
in G0 , we replated the cells onto fibronectin in the presence of either the ROCK inhibitor 
Y-27632 or NSC-23766, to block Rac 1 signaling.  We found that the hyperproliferation 
exhibited by IPAH PASMCs was reduced to levels comparable to those of the control 
cells via treatment with Y-27362. Control PASMCs were significantly less affected by Y-
27632 treatment, but were particularly sensitive to NSC-23766 treatment (Fig. 3.12B).  
These data suggest that PASMCs of patients with IPAH may undergo a Rac-to-Rho 
proliferative control switch.   
To further substantiate whether RhoA signaling might be higher in IPAH cells, 
we compared RhoA activity levels in PASMCs from a single diseased lung and a control 
lung. We found that the IPAH PASMCs have a greater than 2-fold higher RhoA activity 
as compared to the control cells (Fig. 3.12C).  Taken together, these results suggest that 
RhoA signaling is altered in IPAH and that this may underlie the aberrant proliferation of 
IPAH PASMCs. 
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Figure 3.12 Proliferation rates of control and IPAH PASMCs in culture. (A) 
Baseline proliferation of isolated control and IPAH SMCs as measured by BrdU 
incorporation. *, p < 0.05. (B) Proliferation of control and IPAH SMCs after 
treatment with the RhoA inhibitor Y-27632 or the Rac inhibitor NSC-23766. Data 
represent pooled results from all control or IPAH donor cells. *, p < 0.05 for 
comparison of untreated control PASMC vs. IPAH PASMC. #, p < 0.05 for 
comparison of untreated control PASMC vs. drug-treated control PASMC.  ^, p < 
0.05 for comparison of untreated IPAH PASMC vs. NSC-23766-treated IPAH 
PASMC. (C) RhoA activity levels measured in a single control and IPAH donor 
cell population.  *, p < 0.05.  All data (panels A, B, and C) are expressed as ± SEM 
from at least 3 independent experiments. 
 
3.5.2 Adhesion signaling is altered in IPAH PASMCs 
Focal adhesions are mechanical and biochemical linkages between the cell and its 
extracellular environment. Because focal adhesion size is known to be regulated by RhoA 
signaling (Chrzanowska-Wodnicka & Burridge, 1996), we sought to examine whether 
focal adhesion architecture or the expression levels of focal adhesion proteins might be 
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altered in IPAH PASMCs. We first investigated whether differences in the expression of 
vinculin, a key focal adhesion protein, existed in IPAH versus control cells. Indeed, we 
observed that IPAH PASMCs exhibited significantly higher vinculin expression than the 
control PASMCs (Fig. 3.13A). To visualize focal adhesion size and architecture, we 
performed vinculin immunostaining and found that focal adhesions appeared longer in 
IPAH cells versus controls (Fig. 3.13B). Quantification of focal adhesion length revealed 
that adhesions in cells from patients with IPAH were almost 50% larger than those in 
control PASMCs (Fig. 3.13C). 
To investigate whether altered focal adhesion structure might also give rise to 
differences focal adhesion signaling, we measured the phosphorylation status of focal 
adhesion kinase (FAK), a key signaling molecule within focal adhesions. We found that 
IPAH SMCs expressed higher levels of FAK phosphorylated at Y397 
(autophosphorylated FAK) than control cells (Fig. 3.13D). The aberrant focal adhesion 
size and signaling may contribute to the observed proliferation differences. 
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Figure 3.13 Focal adhesion size, structure, and FAK phosphorylation status in 
IPAH PASMCs. (A) Representative blots and quantification of vinculin 
expression in control and IPAH PASMCs. Quantification represents pooled data 
from all control and IPAH donors. *, p < 0.05. (B) Representative 
immunostaining for vinculin in control and IPAH PASMCs. Scale bar: 20 mm. 
(C) Quantification of average focal adhesion length in control and IPAH 
PASMCs. *, p < 0.01. (D) Representative blots and quantification of total and 
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phospho-397 FAK in control and IPAH PASMCs. Data are expressed as ± SEM 
for panels A-C and ± SD for panel D. 
 
3.5.3 High proliferation in IPAH PASMCs is mediated by altered adhesion signaling 
Cell adhesion to the extracellular matrix is a known regulator of cell growth and involves 
the physical spreading of cells against an underlying substrate (C. Chen et al., 1997; 
Raines, 2000). As expected, control PASMCs exhibited a nearly complete inhibition of 
proliferation when cultured on micropatterned substrates in which the geometry of the 
printed patterns limit the cell’s ability to fully spread (Fig. 3.14A). Surprisingly, this 
adhesion-mediated growth control appears to be lost in IPAH PASMCs, which maintain 
their high proliferation rates even in a context of limited cell spreading (Fig. 3.14A). 
Because we have demonstrated that adhesion signaling through FAK is high in IPAH 
PASMC and that these cells exhibit altered adhesion-mediated growth control, we next 
investigated whether pharmacological inhibition of FAK would restore normal adhesion-
mediated growth control in IPAH PASMC. We plated G0-synchronized IPAH PASMCs 
or control PASMCs onto micropatterned islands of fibronectin and treated with the FAK 
inhibitor PF-573,288. Blocking FAK signaling restored normal adhesion-mediated 
growth control mechanisms in the IPAH PASMCs (Fig. 3.14B). Together, these data 
suggest that IPAH PASMCs exhibit altered adhesion signaling, which appears to drive 
their hyperproliferation in culture. 
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Figure 3.14 Adhesion-mediated proliferative control in IPAH PASMCs. (A) 
Proliferation of control and IPAH PASMCs on unpatterned (spread) and patterned 
(unspread) fibronectin-coated substrates. (B) Proliferation of control and IPAH 
PASMCs treated with PF-573,228 and seeded onto patterned fibronectin-coated 
substrates. All data are expressed as ± SEM. *, p < 0.05 for comparison of control 
vs. IPAH PASMC under spread conditions. #, p < 0.05 for comparison of IPAH 
PASMC under spread vs. unspread conditions. 
 
 
3.6 Materials and Methods 
Cell Isolation 
Lungs from IPAH patients were obtained through the Pulmonary Hypertension 
Breakthrough Initiative consortium. The lungs were grossly dissected by following the 
main pulmonary artery and subsequent branches until reaching the terminal vessels. The 
dissected arteries were then divided into three categories based on vessel diameter and 
the adventitia was removed by further dissection. For our studies, vessels with a diameter 
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of 1–5 mm were used. After isolation they were sectioned into approximately 30 mm 
long segments and placed into 100 mm tissue culture dishes with 10 mL SmGM-2 
Smooth Muscle Growth Medium (Lonza). After two weeks, an additional 5 mL of 
growth medium was added, and a 50% change of growth medium was performed after a 
total of three weeks in culture. At this time, any remaining tissue was removed from the 
culture dish, and the remaining PASMCs were cultured under standard conditions as 
described below.  Control PASMC were isolated from patients without pulmonary 
arterial hypertension using the same procedure. 
 
Cell culture and reagents 
PASMCs were cultured in Smooth Muscle Growth Medium-2 (Lonza) and were 
maintained at 37°C in a humidified CO2 incubator. Y27632 and NSC23766 were 
purchased from EMD Biosciences. PF-573,228 was purchased from Tocris.  All 
experiments were performed using cells at passage 8 or earlier. 
 
Proliferation Assays 
Control or IPAH diseased PASMC were G0 synchronized by serum starvation for 24 
hours. Cells were then trypsinized and replated in the presence of BrdU (GE Healthcare). 
Cells were fixed at 24 hours and stained for BrdU incorporation using a monoclonal 
antibody directed against BrdU (GE Healthcare) followed by incubation with an 
AlexaFluor-594-conjugated anti- mouse secondary antibody (Invitrogen). Cells were 
counterstained with Hoechst 33342 (Invitrogen). For inhibitor studies, cells were treated 
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with 25µM Y27632, 50µM NSC23766, or 5µM PF-573,228 at the time of plating after 
synchronization. 
 
Quantitative Real-Time PCR Analysis of Smooth Muscle Cell Markers 
Prior to lysis, cells were grown to confluence, cultured in the absence of serum for 24 h, 
and replated at a density of 5,000 cells/cm2. The cells were then lysed and RNA was 
isolated using the RNeasy Micro Kit (Qiagen). 0.5 µg of RNA from each sample was 
spotted in triplicates into a 96-well PCR plate (ISC BioExpress) along with nuclease-free 
water (Ambion) and oligo(dT) primer (Promega). The plate was heated to 70 oC for 2 
min, after which a master RT-PCR mix containing 5x first strand buffer (Invitrogen), 
dNTP mix (Promega), RNasin RNase inhibitor (Promega) and M-MLV reverse 
transcriptase (Promega) was added. The RT reaction was run using an Eppendorf 
Mastercycler Gradient thermal cycler as follows: 42 oC for 1.5 h, 94 oC for 5 min, hold at 
4 oC. 80 µL water was added to the samples containing cDNA, and they were stored at -
20 oC. Quantitative real-time PCR was performed in triplicate using TaqMan probes 
specific for ACTA2, CNN1, MYOCD, SM22, SMTN and GAPDH (Applied Biosystems) 
with the FAM dye label. The real-time PCR reaction was run using an Applied 
Biosystems 7300 Real- Time PCR System using standard conditions: 2 min at 45 oC, 30 
sec at 95 oC, and 40 cycles of 2 sec at 95 oC denaturation and 60 oC annealing/extension. 
Results were quantified using the comparative CT method with GAPDH used as the 
reference amplification. Data for each marker were normalized to the control PASMC 
sample. 
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Immunocytochemistry, image analysis, and quantitative analysis of focal adhesions 
Quantitative analysis of focal adhesions was performed as previously described (Pirone et 
al., 2006). Briefly, cells were incubated for 1 min with ice-cold cytoskeleton buffer (50 
mM NaCl, 150 mM sucrose, 3 mM MgCl2, 1µg/mL of the following protease inhibitors: 
aprotinin, leupeptin, pepstatin, and 2 mM PMSF), followed by 1 min in ice-cold 
cytoskeleton buffer supplemented with 0.5% Triton-X 100. Detergent extracted cells 
were fixed in 4% formaldehyde in PBS, washed, and incubated with the hVin-1 primary 
antibody against vinculin (Sigma-Aldrich). Vinculin staining was visualized by 
incubation with an AlexaFluor-594-conjugated secondary antibody (Invitrogen). 
Quantitative microscopy of focal adhesions was performed using a SPOT camera 
(Diagnostic Instruments) attached to an inverted microscope (Zeiss, Axiovert 40 CFL) 
using a 63X oil immersion objective. Images were obtained and processed using SPOT 
software (Diagnostic Instruments) to measure the length of individual focal adhesions. 
Approximately 10 cells were analyzed per experimental condition. 
 
RhoA activity assays 
RhoA activity was quantified using an absorbance based G-LISA RhoA Activation Assay 
(Cytoskeleton) according to the manufacturer’s instructions. Briefly, IPAH or normal 
control PASMCs were grown to confluence and serum starved for 24 hours. The cells 
were then plated into fibronectin coated (25 µg/mL) dishes at a density of 7,000 cells/cm2 
and lysed with the provided lysis buffer after 4 hours. Total protein concentration was 
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measured using the supplied reagents and each sample was added to duplicate wells of 
the provided 96-well plate. Following the manufacturer’s protocol, antigen presenting 
buffer, primary antibody solution, secondary antibody solution and HRP detection 
solution were sequentially added to the wells. The signal was read by measuring 
absorbance at 490 nm using a multifunction microplate reader (TECAN GENios, 
TECAN). 
 
Western Blots 
Cells were washed in TBS and lysed in cold RIPA buffer. Proteins were separated by 
denaturing SDS-PAGE, electroblotted onto a PVDF membrane (Bio-Rad Laboratories), 
blocked with 5% milk in TBS, immunoblotted with specific primary antibodies, and 
detected using horseradish peroxidase–conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories) and SuperSignal West Dura (Pierce Chemical Co.) as a 
chemiluminescent substrate. Densitometric analysis was performed using a VersaDoc 
imaging system with QuantityOne software (Bio-Rad Laboratories). 
 
Micropatterned Substrates 
To generate stamps for microcontact printing of proteins, a prepolymer of 
poly(dimethylsiloxane) (PDMS; Sylgard 184; Dow Corning) was poured over a 
photolithographically generated master, as previously described (C. Chen et al., 1997). 
Stamps were immersed for 1 h in 50 µg/ml fibronectin, washed three times in water, and 
blown dry under nitrogen. Coated stamps were placed in conformal contact with a 
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surface-oxidized PDMS- coated glass coverslips. Stamped coverslips were immersed in 
0.2% Pluronic F127 (Sigma-Aldrich) in PBS for 1 h and washed. 
 
3.7 Conclusions 
Organotypic models provide an important intermediate platform between traditional 
tissue culture models and in vivo studies for investigations into disease mechanisms in a 
physiologically relevant context. In previous studies, models of the arterial wall have 
been proposed that utilize sequentially seeded layers of SMCs and ECs to form a bilayer 
mimicking the intimal and medial compartments of arteries (Niwa et al., 2007; Ziegler et 
al., 1995). In the work described here, we have attempted to replicate a version of this 
model using bPAECs and bPASMCs with the eventual goal of employing ECs and SMCs 
derived from patients with IPAH. However, bPAECs seeded onto monolayers of 
bPASMCs treated with ascorbic acid failed to spread and form monolayers. As an 
alternative approach, we sought to generate layers of SMCs cultured atop confluent 
layers of ECs. However, failure to also generate this ‘inverse’ arterial wall model led us 
to abandon these approaches and focus on studying mechanisms regulating the 
proliferation of IPAH PASMCs using more traditional tissue culture models. 
IPAH is characterized by an increase in SMC proliferation and subsequent 
occlusion of the luminal space. While we have a basic understanding of the 
pathophysiology of IPAH as it relates to vascular architecture, the underlying molecular 
etiology of the proliferative-driven thickening of the tunica media remains unclear. In the 
work presented here, we have demonstrated that the regulation of proliferation via Rho 
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GTPase activity and adhesion signaling pathways are dysfunctional in vascular SMCs 
isolated from patients with advanced IPAH. 
Overall, our data presented here suggest the presence of a defect in the 
proliferative regulation mechanisms of SMCs obtained from patients with IPAH. These 
IPAH cells display a higher than normal expression of RhoA, increased focal adhesion 
size, and aberrant focal adhesion signaling, all of which are key in properly modulating 
proliferation. This lack of proliferative regulation via focal adhesions and cell spreading 
is reminiscent of an SMC phenotype found in neointimal lesions of IPAH patients (Chin 
& Rubin, 2008). Taken together, these findings suggest that the underlying etiology of 
IPAH is likely to have a mechanochemical basis.  
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CHAPTER 4: Discussion and Future Directions 
 
4.1 Discussion of patterned endothelial cell cords for vascularizing 
engineered tissues 
4.1.1. In vitro generation of endothelial cell cords 
In the work described in Chapter 2, we have developed a novel strategy for generating 
functional capillaries with spatially controlled geometry in vivo. Our technique relies on 
the implantation of patterned endothelial cell cords into mice. The cords are formed using 
microfabricated PDMS templates to spatially arrange endothelial cells within collagen 
gels. We observed that HUVEC and 10T1/2 cells organized into cords through a 
contractility dependent process and have previously shown that they exhibit proper cell-
cell junction formation (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a). 
Most in vitro approaches for generating constructs for the study of vascular 
biology have focused on creating endothelialized tubes (Chrobak et al., 2006; Miller et 
al., 2012). While these strategies are capable of generating increasingly complex 
architectures, their application has been limited to the creation of large diameter tubules.  
Other studies have demonstrated that endothelial cells seeded onto thin (10 µm) lines of 
patterned matrix also leads to the formation of cords (Dike et al., 1999). While this 
approach is capable of generating geometrically patterned cords, here we demonstrate the 
additional ability to alter cord diameter and, most importantly, the ability to embed the 
cords into implantable tissue constructs for further study in vivo. Our approach for 
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patterning cells into cords is capable of generating complex branched networks and 
geometries that mimic native vasculature within engineered tissues. In addition, because 
the cords in our system are formed in a separate step from their embedding into a 
surrounding material, they can be readily used to combine patterned vasculature with 
parenchymal or other cells. As an example, we demonstrate that aggregates of 
hepatocytes embedded into the matrix surrounding patterned cords exhibit improved 
function due to increased vascular access. 
In the studies described in Chapter 2, EC cords were removed into fibrin, a natural 
ECM material that has been used extensively in angiogenic applications and one whose 
proangiogenic properties of have been well documented (X. Chen et al., 2009; Ghajar, 
Blevins, Hughes, George, & Putnam, 2006; Hall et al., 2001; Lesman et al., 2011). To 
study the effects of ECM properties on vascularization of engineered tissue constructs, 
one might envision embedding cords within ECMs such as PEG hydrogels that allow for 
independently varying material properties (Miller et al., 2010; Moon et al., 2011). Other 
natural ECMs such as Matrigel have been shown to elicit a strong angiogenic response in 
vivo (Passaniti et al., 1992). While our work has been limited to the use of fibrin as the 
proangiogenic scaffold for embedding cords, one could envision studies that utilize a 
variety of materials with different properties to gain better insights into the vascular 
response. 
 Our in vitro characterizations revealed that cords form via the cells’ compaction 
of surrounding ECM using a contractility dependent process and that cells are distributed 
randomly throughout the fully formed cords. Over three decades ago, studies first showed 
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that fibroblasts embedded within a collagen gel progressively contract and reduce the 
diameter of the gel (E. Bell, Ivarsson, & Merrill, 1979). More recently, it has been shown 
that endothelial cells also exhibit similar contractile behavior in collagen gels (Vernon & 
Sage, 1996). Although the cords described here are geometrically different than the discs 
typically used in these contractility studies, it is likely that the contraction we observe in 
cords is driven by the same mechanisms. In their study Sage and colleagues observed that 
endothelial cells contracted collagen gels similarly to dermal fibroblasts. Although the 
traction forces generated by C3H10T1/2 cells have never been assayed directly, it is 
likely that they exhibit similar contractile forces to that of other cells of mesenchymal 
origin such as fibroblasts. Given comparable levels of contraction to that of HUVECs and 
the relatively low abundance of 10T1/2s in our cords, it is not surprising that their 
absence has no measurable effect on the rate or degree of cord formation. To precisely 
tease out the relative contributions of each cell type, one might envision experiments 
involving the direct measurements of traction forces exhibited by each cell type as well as 
measuring the contraction rates of gels formed with varying proportions of the two cell 
types. However, the formation of cell-cell contacts and juxtaposition of neighboring cells 
rather than contractility likely contribute most to the vascularization process in vivo 
(discussed below). 
4.1.2 The vascularization response to implanted endothelial cell cords  
Implantation of tissue constructs containing cords of endothelial cells led to the formation 
of functional capillaries in vivo. We observed that the capillary walls were comprised of 
implanted endothelial cells and became perfused with blood within 3 days PI. Previous 
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studies of engineered vasculature have shown that implanted endothelial cells contribute 
directly to the formation of vessels and persist for up to one year in vivo (X. Chen et al., 
2010; Koike et al., 2004). Our findings that viable cells within cords are required for the 
vascularization response suggest that similar mechanisms of cells organizing into 
lumenized vessels take place within the vascularization strategy described here. 
While our analyses here have been limited to post-sacrifice histology and 
imaging, one might envision the use of longitudinal intravital imaging techniques to 
directly observe the cellular dynamics within implanted cords (Au, Daheron, Duda, 
Cohen, Tyrrell, et al., 2008a; White et al., 2012). Histological studies of implanted EC 
cords indicate that cells of human origin persist within the capillaries for at least 28 days. 
We also observe, however, that these vessels remodel significantly upon formation, 
becoming smaller, invested by pericytes, and more numerous. While no notable 
differences exist between capillaries within cords and the host vasculature, the formation 
process of the engineered is likely unique. Interestingly, events in vascularization upon 
implantation of EC cords resemble early processes in both vasculogenesis and 
angiogenesis. In vasculogenesis, aggregates of angioblasts, or endothelial precursor cells, 
organize around blood islands to form nascent vessels (Risau & Flamme, 1995). In 
angiogenesis, prior to forming a lumen sprouting endothelial cells migrate collectively as 
a ‘cord’ (Adams & Alitalo, 2007). Patterned cords of endothelial cells likely become 
vascularized utilizing a combination of mechanisms that underlie these two physiological 
processes. To shed light on some of the underlying mechanisms that drive the 
vascularization process, one might envision adapting our vascularization strategy for use 
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with longitudinal intravital imaging techniques. Questions particularly worthy of 
investigation using such a system might be: 1) how do implanted ECs sort and migrate to 
form lumenized vessels? 2) what is the fate of implanted ECs that do not become 
incorporated into the walls of capillaries? 3) do implanted 10T1/2 cells contribute to the 
pericyte population observed in mature capillaries? While our data demonstrate the 
successful formation of spatially controlled capillary networks in vivo, further studies 
such as those described above will undoubtedly herald manipulations that allow an 
additional level of control over the vascularization process. 
4.1.3 Role of cell type in the vascularization response upon implantation of 
endothelial cell cords 
A variety of cell types have successfully been used in various strategies for engineering 
microvasculature (Au, Daheron, Duda, Cohen, Tyrrell, et al., 2008a; Au, Tam, 
Fukumura, & Jain, 2008b; X. Chen et al., 2010; Ghajar et al., 2006; Melero-Martin et al., 
2008). Findings by George and colleagues indicate that cell networks formed prior to 
implantation lead to a more robust vascularization response in vivo (X. Chen et al., 2009). 
Here, we confirmed that a 1:50 combination of C3H10T1/2s:HUVECs exhibits extensive 
networking behavior when embedded within collagen gels in vitro. Additionally, 
previous studies have demonstrated that 10T1/2s are capable of contributing to the 
vascularization process by differentiating into smooth muscle cells or pericytes 
(Hirschi et al., 1998). Based on these findings, the majority of studies described here 
were conducted using a combination of 1:50 10T1/2s and HUVECs. Our data suggest 
that nearly all capillaries formed in the implanted cords exhibited the presence of α-
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SMA-positive cells immediately adjacent to the vessel walls. While the HUVECs could 
be readily identified using immunohistochemical techniques due to their human origin, 
we were unable to immunostain the murine-derived 10T1/2s. A study utilizing labeled 
10T1/2 cells (e.g. with GFP) is needed to definitively elucidate their contribution to the 
vascularization process. It could be postulated that alternative mechanisms could be 
responsible for recruiting α-SMA-positive of host origin to the forming vessels. Studies 
have shown that circulating perivascular progenitor cells can contribute to tumor 
angiogenesis (Mancuso et al., 2011). While unlikely, sources of pericytes such as these 
cannot be ruled out until more detailed studies are conducted. Despite lacking knowledge 
on the exact role of 10T1/2s in implanted EC cords, our data and other studies suggest 
that they play a direct role in driving the maturation of newly formed capillaries. 
Previous studies have shown that endothelial cells of various origins exhibit 
different levels of angiogenic potential in vivo (Barclay et al., 2012). While the HUVECs 
employed in our studies have a verified endothelial phenotype including the expression of 
CD31 and von Willebrand factor, their capability to contribute to angiogenesis was not 
directly tested. Vascularization strategies employed by others have utilized a variety of 
cell types including human adult and cord blood derived endothelial progenitor cells and 
human embryonic endothelial cells (Levenberg et al., 2005; Melero-Martin et al., 2008). 
Future studies should focus on the ability of these and other cell types to contribute to the 
vascularization process in implanted EC cords. 
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4.1.4 Role of growth factor signaling in the vascularization response upon 
implantation of endothelial cell cords 
 Previous studies have shown that production of growth factors such as VEGF by 
pericytes is associated with endothelial cell survival (Darland et al., 2003). Additionally, 
PDGF produced by endothelial cells works to recruit and maintain pericytes in a 
differentiated state (Hirschi et al., 1998). Such VEGF/VEGFR and PDGF/PDGFR 
paracrine loops between HUVECs and 10T1/2 cells are likely at the heart of growth 
factor signaling within EC cords. While not directly measured in our studies, previous of 
angiogenic mechanisms have demonstrated that HUVECs respond to canonical 
proangiogenic growth factors such as VEGF (Angulo et al., 2011). Additionally, it has 
been shown that HUVECs modulate the proliferation and differentiation of 10T1/2 via 
PDGF when cultured together (Hirschi, Rohovsky, Beck, Smith, & D'Amore, 1999). 
While these signaling pathways help to regulate HUVEC and 10T1/2 angiogenic 
behavior within cords in vitro, they are subject to an additional milieu of growth factors 
upon implantation. Differentiatied 10T1/2s are known to produce VEGF and maintain 
endothelial cell survival (Darland et al., 2003). Likely, 10T1/2s embedded within cords 
signal not only to adjacent HUVECs but also to the surrounding host tissue. Indeed, our 
data suggest that angiogenic activity leads to capillary formation between adjacent cords 
(Fig. 2.25), a phenomenon that is likely driven by secretion of growth factors from 
adjacent cords. 
Host tissue is undoubtedly affected by growth factor signaling from implanted 
cords. Likely, factors including VEGF and PDGF stimulate angiogenic sprouting from 
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otherwise quiescent host vessels and help to recruit mural cells to forming capillaries, 
respectively. Indeed, it has been shown that implanted endothelial cells elicit a wound 
healing response in host tissue that is regulated by growth factors including VEGF and 
PDGF among others (Soejima, Negishi, Nozaki, & Sasaki, 1998). While our histological 
analyses do not suggest that a host angiogenic response reaches the center of implanted 
constructs, we do observe vessels of host origin near the periphery. Likely, this 
angiogenic response from host vessels is driven in large part by secreted growth factors. 
Localization of growth factor signaling to the periphery of implanted constructs is further 
supported by evidence that secreted VEGF is largely cell- or matrix-bound, effectively 
limiting its ability to signal over large distances (Darland et al., 2003). 
In vivo, growth factors are secreted into the surrounding matrix and form complex 
spatiotemporal gradients within tissues, making their detection and characterization 
particularly challenging (Guo et al., 2012). Additional study into the role of growth factor 
signaling in the vascularization response upon implantation of EC cords could be 
undertaken by loss- or gain-of-function studies and pharmacological inhibition. Namely 
HUVECs or 10T1/2s lacking VEGF, PDGF, or their receptors might be used to generate 
cords. Subsequent implantation and histological analyses would shed light on the 
requirements of these angiogenic factors in the vascularization response. Specifically, it 
might be hypothesized that VEGF production by the implanted cells is required to elicit a 
proper angiogenic response from the surrounding host tissue. Thus, it would be 
interesting to investigate whether implantation of VEGF-null cells would still result in 
proper anastomosis and connection with the host vasculature. Additionally, one might 
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envision the use of pharmacological inhibitors of growth factor receptors to probe their 
roles in different stages of the vascularization response. For example, PDGF inhibitors 
could be introduced at day 5 post-implantation to determine whether it is required for 
capillary maturation. Lastly, materials with controlled-release properties might be 
employed to gain a degree of control over the delivery of the growth factors (Laham et 
al., 1999; Lin & Anseth, 2008). Use of such materials, however, would first require a 
thorough characterization of their capabilities in driving vascularization in tissue 
constructs containing EC cords. 
4.1.5 Role of the extracellular matrix in the vascularization response upon 
implantation of endothelial cell cords 
To date, a variety of natural and synthetic matrices have been used for generating 
vasculature in vivo (Lovett et al., 2009; Moon et al., 2011; Peters et al., 2002; Phelps & 
García, 2010). In the system described here, the combination of type I collagen and fibrin 
provides a permissive environment for vessel formation that consists of natural ECM 
materials that can be remodeled by cells over time. Both fibrin and collagen have been 
extensively used in tissue-engineered vascularization strategies and the proangiogenic 
activity of fibrin is well documented (X. Chen et al., 2009; Hall et al., 2001; Lesman et 
al., 2011; Oh, Lu, Kawazoe, & Chen, 2011; A. Y. Wang et al., 2008). The regulation of 
angiogenesis by ECM is largely manifested through its degradation by matrix 
metalloproteinases (Ghajar, George, & Putnam, 2008b). Here, we observed signs of fibrin 
degradation as early as 7 days PI. Likely, this degradation is a required and permissive 
cue for the sprout formation that we observed between capillaries in adjacent cords and at 
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the edges of implanted constructs. While these findings suggest that cells within cords 
actively remodel the fibrin matrix upon implantation, it is not clear whether MMP 
activity is required for the vascularization process. Indeed, because the ends of EC cords 
are often exposed near the edges of the encapsulating fibrin gel, matrix degradation may 
not be required for the host vasculature to enter into contact with the implanted cords. 
Given the rapid rate of vascularization that we observed, it is plausible that MMPs may 
only become upregulated over time as newly formed vessels begin to remodel. 
Interestingly, we observed no signs of collagen degradation within the cords. Studies 
have shown that specific MMPs, namely MT1-MMP, play a pivotal role in angiogenic 
processes both in vitro and in vivo (Collen et al., 2003). Given that various MMPs act 
selectively on the various ECM components, it would be especially interesting to 
examine their secretion patterns within tissue constructs containing EC cords. Ultimately, 
more elaborate studies employing MMP-resistant synthetic materials or genetic 
manipulations of MMP expression within implanted cells could be used to gain further 
insights into their role in the vascularization response described here. 
 When cultured cells are placed in a three dimensional environment such as within 
a gel of ECM, their proliferation rates typically decrease significantly (Cukierman, 
Pankov, & Yamada, 2002; Cukierman, Pankov, Stevens, & Yamada, 2001). In addition, 
quiescent endothelial cells, whether in a monolayer on a tissue culture dish or in patent 
vessel wall, exhibit very low rates of proliferation (S. M. Schwartz & Benditt, 1977). 
These trends suggest that cells within the EC cords used in our studies also proliferate at 
relatively low levels upon implantation. Accordingly, histological analysis did not reveal 
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cell numbers within cords that appeared to be dramatically higher than those originally 
implanted. This observation, however, is strictly qualitative and the question of 
proliferation has not yet been fully explored within our system. Immunostaining for 
proteins involved in cell cycle progression such as Ki-67 could be used a simple for 
increased proliferation in the implanted cells. 
4.1.6 Role of cell-cell contacts in the vascularization response upon implantation of 
endothelial cell cords 
We have demonstrated that implanted cords of ECs become rapidly perfused with host 
blood upon implantation and form mature capillaries after just 7 days. While our results 
show that these capillaries are comprised of juxtaposed endothelial cells, the precise role 
of cell-cell contacts during capillary formation remains to be fully explored. Endothelial 
cell-cell contacts are known to play a vital role in angiogenesis and vessel homeostasis 
(Adams & Alitalo, 2007; Nguyen & D'Amore, 2001). In the context of engineered 
vasculature, previous studies have shown that increasing the amount of cell-cell contact 
between endothelial cells by ‘preculturing’ them for one week prior to implantation leads 
to enhanced vascularization in vivo (X. Chen et al., 2009). These studies led us to 
hypothesize that increased cell-cell contacts between ECs patterned into cords would 
allow them to rapidly form patent vessels while maintaining the geometry of the cords. In 
a previous study, we have shown that extensive CD31 cell-cell junctions form between 
adjacent ECs within cords (Raghavan, Nelson, Baranski, Lim, & Chen, 2010a). It is 
likely that the densely packed arrangement of HUVECs within cords allows them to form 
numerous other types of cell-cell contacts including adherens and gap junctions. 
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Formation of such contacts might allow cells within cords to act as a collective unit, 
much like an angiogenic sprout, and quickly form patent vessels upon the introduction of 
blood. While we have already shown that cords contain CD31 cell-cell junctions, the 
presence of adherens and gap junctions could be confirmed via immunostaining for their 
components including VE-cadherin and connexin 43, respectively. Such characterization 
would pave the way for subsequent loss-of-function studies that might be used to directly 
test the requirements for the presence of established cell-cell junctions during capillary 
formation. Viral delivery of dominant negative mutants of VE-cadherin, N-cadherin (for 
interfering with EC-10T1/2 interactions) or connexin 43 prior to cord formation could be 
utilized for this purpose. Because cord formation appears to be driven by cytoskeletal 
contractility, it is not likely that knockout of these proteins would interfere with this 
process in vitro. Indeed, one might hypothesize that the relatively high cell density even 
in uncontracted cords might be sufficient for extensive cell-cell contacts to rapidly form. 
Consequently, the contraction phase of cord formation might not be required for the 
vascularization response that follows their implantation. 
Further histological studies such as those described in Chapter 2 will provide 
insights into whether mature cell-cell junctions within cords are required for their ability 
to drive capillary formation in vivo. Quantifiable outputs of these studies should include 
the rate of vascularization (time required until evidence of blood, lumenized vessels), 
vessel patency/leakiness, and long-term vessel stability. Implantation of heterologous 
cells or tissues such as EC cords requires the use of immunodeficient host animals. This 
requirement combined with lethal defects in animals whose cells are unable to form 
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proper adherens or gap junctions limits loss of function studies to the realm of 
manipulations of the implanted materials (Carmeliet et al., 1996; Radice et al., 1997; 
Reaume et al., 1995). Additional insights into the role of cell-cell contacts in driving the 
vascularization response could be achieved via gain of function experiments. 
Specifically, one might test whether overexpression of junctional proteins could be used 
to speed up or otherwise alter the vascularization response. If such manipulations were to 
speed up vascularization, a particularly interesting follow-up experiment would be to 
transiently overexpress the implicated junctional proteins. In such a model, one might 
hypothesize while initially higher expression levels help to drive a rapid and robust 
vascularization response that quickly produces patent vessels, the eventual return of the 
expression levels to baseline might be necessary to ensure proper vessel function over the 
long term. Overall, given the importance of cell-cell contacts in angiongenesis and 
homeostasis in quiescent vessels, it is likely that they play a significant role in the 
mechanisms underlying vascularization in our system. 
4.1.7 Anastomosis with the host vasculature 
Studies by George and colleagues have suggested that engineered capillary networks can 
anastomose with host vasculature within 1 day of implantation (X. Chen et al., 2010). 
Here, we have observed that implanted EC cords become perfused with blood within 3 
days of implantation. Venous introduction of fluorescent dextran further confirmed that 
capillaries within the cords are perfused with host blood after 2 weeks. The underlying 
mechanisms of host-graft anastomosis in our system have not been fully elucidated, 
however. Findings by Jain and colleagues have suggested a ‘wrapping-and-tapping’ 
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mechanism of anastomosis in engineered tissues (Cheng et al., 2011). Here, injections of 
lectins specific for mouse or human endothelium have suggested that some cells of 
mouse origin are present within the vessel walls near the edges of implanted constructs. 
These data suggest that an angiogenic response from the host tissue is elicited, causing 
typically quiescent host vessels to sprout and eventually connect with capillaries forming 
within the implanted cords. Presence of solely this mechanism, however, seems unlikely 
and would contradict the findings by Jain and colleagues. While not yet directly 
observed, we predict that a ‘wrapping-and-tapping’ mechanism of anastomosis might 
also play a role in the vascularization response described here. 
 Over the last several years, advanced methods for longitudinal intravital imaging 
of angiogenic processes in rodents have been developed (Koike et al., 2004; White et al., 
2012). These imaging methodologies must now be adapted for use with the 
vascularization strategy described here in order to better understand the mechanisms that 
underlie host-graft anastomosis. Correctly predicting and imaging areas where 
anastomosis might occur remains difficult in current vascularization approaches. 
Interestingly, employing longitudinal intravital imaging techniques in conjunction with 
our vascularization strategy might not only provide insights into mechanisms of 
anastomosis within our system, but also enable investigators to more readily observe 
anastomotic events. We have recently been able to elicit a vascularization response in 
tissue constructs implanted subcutaneously by utilizing a mesh backing material. These 
results suggest that monitoring of cellular dynamics and subsequent anastomosis within 
an implanted window chamber is feasible. 
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 In addition to the canonical interactions between tip cells in anastomosing 
angiogenic sprouts, research has recently shown that macrophages also play a role in 
guiding the sprouting tips (Fantin et al., 2010). The studies described here were 
performed in athymic mice, which, despite decreased immune function, possess the 
ability to recruit macrophages to sites of injury. It is plausible that these cells might be 
directly involved in the anastomosis of EC cords with host circulation. Experiments 
including longitudinal in situ imaging described above and immunostaining for host 
macrophages would shed additional light on this hypotheses. 
4.1.8 Patterning of vasculature via implantation of endothelial cell cords 
Spatial patterning of vessel architecture is necessary for the design of complex functional 
vasculatures in engineered tissues (Vacanti, 2012). Previous studies have utilized 
physical constraints such as PDMS templates or patterns of ECM-bound VEGF to guide 
the host angiogenic response (Oh et al., 2011; Zheng et al., 2011). Additionally, general 
approaches for vascularizing engineered tissues are limited to prevascularization of 
constructs via self assembly of randomly distributed cells into rudimentary capillary 
networks (X. Chen et al., 2009; Koffler et al., 2011; Koike et al., 2004; Melero-Martin et 
al., 2008). 
Here, via implantation of patterned EC cords, we have demonstrated one of the first 
strategies for directly patterning capillaries in vivo. The geometry of the vasculature is 
determined by directly patterning EC cords using a PDMS template that can be fabricted 
to take a variety of shapes. Perfusion of the vasculature with fluorescent dextran showed 
that spatial organization is preserved following implantation of either parallel arrays or Y 
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shaped networks of cords. We hypothesize that in vivo, the shape of the resulting 
capillary network is determined by both the initial topology of EC cords and the 
persistence of collagen. Histological analyses suggest that the collagen ‘cores’ within 
implanted cords showed no signs of degradation even 28 days PI. These findings suggest 
that the collagen cores, by providing persistent adhesive cues to the implanted cells, 
allow them to better maintain their original conformation and form capillaries in situ. 
Attempts at controlling vessel diameter by implanting EC cords with varying 
diameters did not result in vessels that varied in size. Instead, numerous capillaries 
adjacent to the collagen core were evident in cords of all sizes. These data suggest that 
vessel diameter cannot be controlled via the implantation of larger cords. Indeed, large 
vessels formed during development grow over a period of time rather than forming 
spontaneously via vasculo- or angiogenesis (Adams & Alitalo, 2007). Additionally, 
current approaches to engineer large vessels rely on complex methods that rely on the 
generation of a physiologically accurate vessel in vitro (Matsumura, Hibino, Ikada, 
Kurosawa, & Shin'oka, 2003). Thus, it is likely that future integration of larger vessels 
into constructs with patterned EC cords will require a hybrid approach that combines two 
distinct strategies for generating both larger caliber vessels and small capillaries. 
Histological analyses revealed that implantation of EC cords fabricated using 150 
µm wide microchannels results in the formation of several capillaries in each cord. Given 
these results, one might hypothesize that an excess of implanted cells is driving the 
formation of these multiple capillaries and that formation of single capillaries might be 
possible by utilizing smaller microchannels (e.g. 10 µm) for generating cords. While such 
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an approach would yield much greater control of the fidelity of the final vascular 
architecture, it is also possible that the smaller number of cells per cord would result in a 
less robust response upon implantation. Ultimately, studies such as these will be 
necessary to better understand the extent of control that is possible over capillary network 
geometry. 
4.1.9 Remaining challenges for vascularization of engineered tissues via 
implantation of endothelial cell cords 
Perhaps the biggest challenge in tissue engineering today is the generation of properly 
vascularized solid tissues (Vacanti, 2012). In the study presented here, we have 
demonstrated the ability to generate a functional, patterned capillary network within 
engineered hepatic tissues. While capillaries generated within the hepatic constructs 
significantly increased albumin promoter activity over hepatocyte-only controls, the 
overall levels of albumin produced were below physiologically relevant level. One of the 
next steps in developing clinically viable engineered therapies is the scale up of the 
vascularization technique to generate tissues that can replace or augment tissue function 
in the host. Indeed, as many as 2x109 isolated hepatocytes are currently used in human 
transplantation trials (Baccarani et al., 2005). In the hepatic constructs described here, 
which contained at most one hundred thousand hepatocytes, the amount of albumin 
secreted into the blood stream was very low. Next, we plan to generate constructs with an 
increased number of hepatocytes and potential to augment liver function. A challenge 
associated with this goal is that of successfully integrating patterned EC cords within a 
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larger hepatic construct. We anticipate overcoming this goal by generating multilayered 
tissue constructs. 
Another challenge in the further development of our vascularization strategy is 
that of implantation into non-immunosuppressed hosts. Most likely, an ‘all-rat’ model 
could be used to demonstrate effectiveness in wildtype animals. Specifically, EC cords 
could be generated using isolated rat endothelial and smooth muscle cells. While the 
angiogenic potential of various endothelial cell lines may be different, we do not foresee 
any additional complications in demonstrating feasibility in non-immunosuppressed 
hosts. Ideally, cell-free approaches will ultimately ameliorate the need for cells and 
overcome this challenge altogether. 
Lastly, long-term studies must be performed to better understand the stability of 
the vessels over time. Jain and colleagues have demonstrated the persistence of an 
engineered vasculature up to one year in vivo (Koike et al., 2004). Here, the current end 
point of 28 days does not allow for extensive remodeling and long-term function of the 
vasculature. While capillaries formed within cords appear to recruit pericytes and are 
non-leaky after 7 days, their prolonged function in an engineered tissue remains to be 
tested. A potential complication in these types of studies may be the effectiveness of the 
ECM material to provide proper structural support to the vessels. It is possible that 
degradation of the surrounding fibrin matrix might compromise the integrity of the entire 
tissue construct. Synthetic materials with controlled mechanical properties and 
degradation rates may prove helpful in addressing these issues. 
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4.2 Discussion of studies on proliferative regulation in IPAH SMCs 
4.2.1 Generation of an in vitro arterial wall model 
The mature arterial wall consists of an inner layer of endothelial cells surrounded by a 
contractile smooth muscle layer, and abnormal cell behavior within the media contribute 
to the pathogenesis of many vascular diseases including atherosclerosis and hypertension 
(Chin & Rubin, 2008; Lusis, 2000). Most studies of diseased smooth muscle cells, 
however, are limited to simple tissue culture models that utilize SMCs alone or animal 
models that severely limit the scope of possible manipulations. Previous work has shown 
that treatment of smooth muscle cells in culture with ascorbic acid stimulates the 
expression of smooth muscle-specific markers and increases the synthesis of collagen 
(Arakawa et al., 2003; Barone et al., 1985; Qiao et al., 2009). Based on these findings, we 
sought to generate an in vitro arterial wall model by culturing a monolayer of endothelial 
cells atop smooth muscle cells embedded within a collagen matrix. While an EC-SMC 
bilayer is itself not novel, few studies have reported the use this model in studies of 
vascular disuse (Fillinger et al., 1997; Niwa et al., 2007). 
 Our findings indicated that endothelial cells, even when seeded at high densities, 
did not attach and spread to form monolayers. Instead, our results suggest they do not 
spread extensively and intergrade into the confluent layer of smooth muscle cells, 
perhaps even attaching directly to the underlying glass substrate. Although we did not 
perform imaging of the EC-SMC layers in cross section, it is likely that the amount of 
ECM deposited by SMCs at the time of EC seeding was not high enough to prevent the 
ECs from making contact with the glass substrate. Indeed, previous studies describing the 
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development of arterial wall models relied on an exogenous collagen gel to fully 
encapsulate the SMC layer prior to seeding ECs (Niwa et al., 2007; Ziegler et al., 1995). 
In addition to the quantity of ECM deposited by SMCs, its identity must also be 
considered. Endothelial cells have been shown to form monolayers when cultured on type 
I collagen gels and this method is a routinely used model of angiogenic sprouting 
(Bayless, Kwak, & Su, 2009; W. Koh, Stratman, Sacharidou, & Davis, 2008). Culture of 
endothelial cells atop other matrices such as reconstituted basement membrane 
(Matrigel), however, elicits networking behavior (Goodwin, 2007). It is plausible that the 
more complex matrix secreted by SMCs treated with ascorbic acid contains components 
that prevent the ECs from forming a fully confluent monolayer. It could be hypothesized 
that one such component of the secreted matrix might be elastin, whose deposition has 
also been shown to be increased upon stimulation with ascorbic acid (Barone et al., 
1985). Lastly, the source of the cells used in the generation of an arterial wall model must 
be considered. While in our studies we have used bPAECs, the studies previously 
mentioned in this section have mostly utilized HUVECs. Given that endothelial cells 
from different sources possess various levels of angiogenic potential, the studies 
described here should be tested using HUVECs (Auxenfans et al., 2011). The initial goal 
of our studies was to develop an arterial wall model in which ECs and SMCs derived 
from the lungs of patients with IPAH could be used. Because of the potential for different 
responses due to cell source, such a system will have to be thoroughly tested for 
robustness with endothelial cells from a variety of sources including human adult lungs. 
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 Given the inability to recreate the published arterial wall models described here, 
we decided to pursue an understanding of IPAH SMC pathology in more traditional 
tissue culture models. If future attempts at using these cells to generate EC-SMC bilayers 
is to be made, several considerations must be taken. First, a more thorough 
characterization of confluent SMCs treated with ascorbic acid is necessary. 
Immunofluorescent staining of cultures for collagen I and elastin should be performed to 
better understand the composition of the secreted matrix, while sectioning and 
histological should be used to observe the physical properties of the cell layers in cross 
section. Second, the use of exogenous collagen matrix should be considered. While 
allowing the cells to deposit their own ECM is preferable due to physiological relevance, 
production of type I collagen within the medial compartment has been observed in vivo 
(Rattazzi, Bertacco, Puato, Faggin, & Pauletto, 2012; Wolinsky, 1970). Thus, inclusion 
of exogenous collagen might not have a negative impact on the physiological relevance 
of an arterial wall model and should not be ruled out. Lastly, parameters for seeding cells 
within the system such as numbers of cells used and the length of ascorbic acid treatment 
should be further explored. Namely, the number of endothelial cells used and length of 
culture should be extended. By utilizing DiI-AcLDL and seeding larger numbers of ECs 
seeded atop SMCs, more favorable results are likely to be achieved. In summary, with the 
incorporation of these changes we predict that an arterial wall model could be used to 
better study IPAH PASMC biology in an in vitro setting. 
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4.2.2 Mechanisms underlying abnormal proliferation in IPAH smooth muscle cells 
Results described in Chapter 3 indicate that PASMCs isolated from lungs of patients with 
IPAH exhibit increased proliferation when cultured in vitro. While hyperproliferation in 
PAH SMCs has previously been documented (Chin & Rubin, 2008), our insights into the 
underlying abnormal regulation of proliferative control in IPAH SMCs provide a novel 
insight into the pathobiology of the disease. 
Here, we show that IPAH SMCs exhibit increased RhoA activity and larger focal 
adhesions. These findings are likely explained by previous studies, which have shown 
that increases in Rho-dependent contractility lead to the aggregation of integrins into 
focal adhesions (Chrzanowska-Wodnicka & Burridge, 1996). While not statistically 
significant, data presented here also suggest that myosin light chain phosphorylation 
might be increased in the IPAH cells. More in depth studies of MLC phosphorylation in 
conjunction with immunostaining for integrins would help clarify whether similar 
mechanisms underlie the hyperproliferative behavior in IPAH SMCs. 
Next, our investigation into focal adhesion signaling showed that higher levels of 
FAK are phosphorylated in IPAH SMCs as compared with control cells. This finding is 
consistent with studies that demonstrate that overexpression of FAK leads to G1/S cell 
cycle progression (Gilmore & Romer, 1996; Zhao, Reiske, & Guan, 1998).  Our findings 
also suggest that increased FAK activity in the IPAH PASMC prevent their ability to 
normally regulate adhesion-mediated proliferative control. FAK, a key effector in focal 
adhesion signaling, is involved in their formation, which allows for cell spreading and the 
establishment of cytoskeletal tension (Burridge & Chrzanowska-Wodnicka, 1996; C. 
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Chen et al., 1997; Chrzanowska-Wodnicka & Burridge, 1996; Guan & Shalloway, 1992; 
Kornberg et al., 1992; Lewis & Schwartz, 1995; Pirone et al., 2006; Richardson et al., 
1997; Roovers & Assoian, 2003).  Notably, FAK has been implicated as a key player in 
adhesion-mediated proliferative control via the RhoA signaling pathway, which is 
downstream of cell adhesion to the extracellular matrix (Chrzanowska-Wodnicka & 
Burridge, 1996; Pirone et al., 2006). Additionally, FAK has been shown to regulate the 
activity of RhoA, which is required for sustained ERK signaling and cell cycle 
progression (C. Chen et al., 1997; Danen et al., 2000; Raines, 2000; Ren & Schwartz, 
2000; Welsh et al., 2001). Given the central role of FAK as a signaling hub between the 
extracellular environment and intracellular signaling, it is not surprising that it may play a 
role in the abnormal proliferative regulation observed in SMCs in a disease that involves 
significant mechanical and biochemical changes to the extracellular environment. To 
better understand the role of adhesion signaling in IPAH, we suggest that subsequent 
studies focus on investigating whether proliferation of IPAH PASMCs can be controlled 
via changes to their adhesive microenvironment. Specifically, cells could be plated on 
compliant gels or even embedded in a three dimensional arterial wall model such as that 
described above. Measurements of FAK and Rho activity in these contexts of altered 
adhesion might shed further light on the causative agents in the hyperproliferative 
phenotype previously observed. In the more immediate future, our experimental plans 
focus on confirming that FAK inhibition via genetic manipulations leads to a restoration 
of normal proliferative behavior in the IPAH SMCs. 
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4.2.2 Assessing the phenotype of IPAH smooth muscle cells 
One of the biggest challenges in studies of rare diseases such as IPAH is the ability to 
acquire reliable source material. Due to the relatively low prevalence of PAH, 
approximately 1300 cases per million, the number of patients with the potential to donate 
tissue or other source material is extremely limited (McDonnell, Toye, & Hutchins, 
1983). The resection of lung tissue is a highly invasive procedure that cannot be justified 
for the purpose of acquiring research material. Thus, the majority of human lung tissue 
used in the study of IPAH is obtained from patients who have undergone lung 
transplantation. Because transplantation is a treatment option of last resort, however, cells 
in these lungs have often been subjected to a variety of treatments for several years. 
Ultimately, human cells isolated and used in any in vitro study of IPAH mechanisms are 
likely to exhibit considerable levels of heterogeneity. We acquired cells from IPAH 
patients via laboratories at the University of Pennsylvania participating in the Pulmonary 
Hypertension Breakthrough Initiative. Using cells from this single source insured a 
consistent level of quality control – all SMCs were isolated, propagated and frozen using 
identical protocols. Factors such as age, sex and clinical history, however, were not 
controlled due to the scope of the study. Indeed, the data presented in Chapter 3 
represents findings from at most 3 diseased and 3 control samples. In future studies, 
larger cohorts will be necessary to ensure no bias is introduced due to donor variability. 
Similar challenges are faced when selecting control cells for use in these studies. 
While commercially available sources of human pulmonary artery smooth muscle cells 
ensure a high level of consistency and quality control, their methods of isolation 
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(including source within the lungs), propagation, maintenance and cryopreservation do 
not match that of the independently acquired PAH cells. In order to mitigate some of this 
bias here, we have used control cells that were obtained through both commercial sources 
and isolated at the same laboratories as the IPAH cells. Our findings, however, should be 
independently validated as additional donor cells become available. 
4.2.3 Clinical translation of findings 
The insights into abnormal proliferative regulation in IPAH SMCs presented in Chapter 3 
require additional validation to have direct applications in the clinic. First and foremost, 
our findings must be validated in a larger study. Such a study should include several 
additional lines of donor control and IPAH cells and should include additional 
manipulations not performed here. While we have shown initial evidence that inhibition 
of FAK in an unspread context results in the return of proliferation to normal levels in 
IPAH SMCs, additional studies utilizing genetic manipulations in larger donor cell 
populations might help to solidify the link between FAK and proliferation in IPAH. 
Specifically, overexpression of dominant negative FAK or Rho in additional donor cells 
might be used to validate our proposed mechanism of proliferative misregulation.  
 Next, potential drug targets must be identified in animal models of pulmonary 
hypertension such as hypoxia or monocrotaline treatment in rats (Stenmark, Meyrick, 
Galie, Mooi, & McMurtry, 2009). While our data suggest that FAK inhibition has the 
potential to restore proliferation in IPAH SMCs to normal levels, its inhibition must be 
tested in vivo. Recently, the inhibition of smooth muscle myosin and RhoA, both 
downstream effectors of focal adhesion signaling, have shown promise in animal models 
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(Ho et al., 2012; E. Z. Xu et al., 2010). While these treatments offer to reduce pulmonary 
arterial pressure via vasodilatory effects, our work suggests that further studies into their 
potential antiproliferative effects might also be warranted. Given that our data have 
demonstrated a mechanosensitive component to the abnormal proliferation in IPAH 
SMCs, an eventual cure might involve inhibition of molecules such as FAK or integrins, 
which act as signaling hubs between the extracellular environment and intracellular 
pathways. 
 
4.3 Future directions 
4.3.1 Applications of vascularization via patterned EC cords 
Vascularization of engineered tissues is perhaps the biggest obstacle that we face toward 
the development of clinically viable tissue engineered therapies (Jain et al., 2005; 
Rouwkema et al., 2008; Vacanti, 2012). Here, we have demonstrated the ability of our 
vascularization strategy to be incorporated into engineered hepatic microtissues. While 
much work still remains to be done in order to scale this approach up to larger tissues, we 
believe that this is largely an engineering problem and expect no significant biological 
barriers. Ultimately, we propose that large scale versions of our technique might be 
employed to rapidly and effectively vascularize complex tissues such as liver, kidney and 
pancreas. As a first step in achieving clinical efficacy, such engineered tissues are likely 
to only augment failing tissue function rather than provide a complete organ replacement. 
Challenges including cell source, immunogenicity, and host-graft integration must be 
overcome on the road to true organ replacement therapy. 
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Additionally, we envision vascularization via implantation of patterned EC cords 
as having the ability to vascularize wounds or areas of ischemic tissues. Specifically, gels 
containing cords could be used as a dressing in applications such as diabetic ulcers and 
infarcted cardiac tissue. A particular challenge in the area of wound treatments will the 
that of source material. In situations requiring the revascularization of ischemic tissues, 
the length of time until initiating the treatment is critical for ensuring the best clinical 
outcomes. To overcome these challenges, future research should focus on identifying 
sources of autologous cells that are amenable to rapid isolation, expansion, and use in 
implantable tissue constructs/wound healing materials. 
 In a research setting, we propose that vascularization via EC cords might be used 
as a model to study the effects of vascular architecture on the efficiency of nutrient 
delivery and waste removal via the circulation. Currently, much is known about the 
mechanisms underlying vascular patterning (LaRue et al., 2003). Studies have also shown 
that an increased level of vascular patterning in engineered tissue improves the 
engraftment and vascularization rates of those tissues (X. Chen et al., 2009; Koffler et al., 
2011). However, it is not currently well understood what is the optimal topology of 
vascular architecture in tissue engineered contexts. This area has been poorly studied 
largely due to the lack of an experimental technique that allows for the patterning of 
vessel networks in vivo. We propose that the method of patterning capillaries described 
here could be used to study how different vascular architectures affect the delivery of 
oxygen and nutrients to surrounding tissues in vivo. It would be of particular interest to 
embed cells containing reporters of metabolic activity within the parenchyma of 
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engineered tissues containing varying topologies of EC cords. Combined with in vivo 
imaging, these types of experiments could be used to test a variety of models of optimal 
tissue architecture. 
Lastly, we envision the development of diagnostic tools that utilize tissue 
engineered constructs at their core. While these types of technologies will surely require 
years of research to reach the clinic, vascularization techniques such as the one described 
here might lie at the core of these approaches. Real-time monitoring of various 
circulating biomarkers is an area of particular interest (Ardill & O'Dorisio, 2010; De 
Mattos-Arruda, Olmos, & Tabernero, 2011; Masson, Latini, & Anand, 2010). Rather than 
externally tapping into existing vessels, we envision implantable devices or sensor-laden 
tissue constructs that become vascularized independently. In such an application, 
predicting areas that will become vascularized will be of key importance. Thus, strategies 
for patterning vessels such as the one described here could be used in the development of 
these technologies. 
4.3.2 Future understanding of proliferative regulation in IPAH 
Management of PAH has improved significantly over the last decade, and patients now 
experience a higher quality of life (Agarwal & Gomberg-Maitland, 2011). New 
treatments, however, continuously rely on the same categories of drugs to treat symptoms 
of the disease with no clear signs of an emerging cure. We believe that mechanistic 
studies such as the work presented in Chapter 3 are critical to further uncovering the 
pathogenesis of IPAH. Here, our data suggest that abnormal SMC proliferation in IPAH 
has a mechanical or adhesive component. Identifying the source of these extracellular 
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cues should will be the focus of our future studies in this area. Elucidating the causative 
factors that create a permissive microenvironment for abnormal proliferative regulation in 
PASMCs could lead to the discovery of an underlying cause of IPAH and pave the way 
for the development of future therapies. Lastly, it should be noted that efforts that 
implicate other signaling factors such as PDGF in the etiology of IPAH are currently 
underway (Ikeda et al., 2010). Future investigations into whether these pathways overlap 
with the proliferative misregulation we report here will be key to identifying drug targets 
and gaining a broader understanding of the pathobiology of IPAH.  
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